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INTRODUCTION 
 
Arsenic is a natural substance that has been used medicinally for over 2400 years 
[130]. In 1878, potassium arsenite was reported to have an anti-leukemic effect and 
was used for this purpose in the late 19th and early 20th centuries until it was replaced 
by busulfan in the 1950s [32, 34, 111]. In the modern era, interest in arsenic as a 
chemotherapy was rekindled after it was identified as an active ingredient in 
traditional medicines in China [24, 54, 68]. Arsenic drugs have been generally used 
for the treatment of malignant hematologic diseases [54, 114]. Although arsenic has 
been known as a poison, but it has been generally well tolerated as a therapeutic 
entity.  
As2O3 has been confirmed to be an effective treatment for acute promyelocytic 
leukemia (APL) both in patients with newly diagnosed APL and in those with 
refractory and relapsed APL [42, 43, 91, 109, 112, 115, 142]. The inhibitory effects of 
As2O3 have been shown not only in parental APL NB4 cells [14], but also in retinoic 
acid-resistant APL cells [9]. It has been reported that the effects of As2O3 are not 
confined to APL cells but can also be observed in various other cell lines of myeloid 
[125] and lymphoid origin [108, 143, 144] and in drug resistant sublines [31, 97]. The 
mechanisms of action of As2O3 in APL and other malignancies are thought to involve 
inhibition of growth and induction of apoptosis [1, 9, 14, 24, 143, 144].  
MOLT-4, a human T-lymphoblastoid leukemia cell line, has been used 
extensively for studies of leukemia cell biology and antileukemia therapy [4, 25]. We 
have established a daunorubicin resistant MOLT-4 subline (MOLT-4/DNR) by 
exposing the parental MOLT-4 cells stepwise to increasing concentrations of DNR 
over 3 months [77]. These resistant MOLT-4/DNR cells have been shown to 
overexpress functional P-glycoprotein (P-gp) and MDR1 mRNA [77]. P-gp, a product 
of the multidrug resistance (MDR) gene, is a transmembrane efflux pump for different 
lipophilic compounds, including many anticancer drugs and fluorescent dyes [11, 12]. 
Intracellular drug accumulation in cells expressing functional P-gp has been found to 
be decreased as a result of drug efflux [26]. Most of the drugs excreted via this efflux 
pump are hydrophobic organic compounds, and As2O3 may not be excluded from 
drug-resistant cell lines expressing functional P-gp. However, whether As2O3 affects 
the growth of lymphocytic leukemia cells expressing functional P-gp, or the 
expression and/or function of P-gp, is unknown. Some data indicate that As2O3 is not 
sensitive to the drug efflux pump mechanisms of resistance [26, 142].  
Thus, in Chapter 1, the effects of As2O3 on the growth of and apoptosis in 
parental MOLT-4 and resistant MOLT-4/DNR cells were investigated. These 
suppressive effects of As2O3 were also related to P-gp expression or function in 
MOLT-4/DNR cells. 
Some reports suggest that sensitivity to As2O3 correlates with intracellular 
glutathione (GSH) levels in cancer cells [138]. The GSH content modulates the 
growth-inhibitory and apoptosis-inducing effects of arsenicals [18, 60, 92, 93, 105]. 
Cells expressing higher levels of GSH or GSH-associated enzymes are less sensitive 
to As2O3 than cells expressing lower levels of these molecules [60, 72]. Arsenic 
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resistant cells are also reported to contain higher levels of GSH [66, 72, 78]. Moreover, 
cells with increased GSH levels can be sensitized to As2O3 by agents that deplete 
intracellular GSH [18, 66]. The cytotoxic effects of As2O3 may be influenced by 
modulators of GSH [31, 33, 67, 89], especially in drug-resistant cell lines [28, 100]. A 
decrease in cellular GSH level acts as a potent early activator of apoptosis signaling 
[3]. Depletion of GSH, especially mitochondrial GSH, is believed to induce the loss 
of mitochondrial membrane potential (MMP) [84]. Mitochondrial permeability 
transition resulting from intracellular thiol depletion is known to be a critical event in 
apoptosis [75, 136]. Mitochondria undergoes major changes in membrane integrity 
before classical signs of apoptosis become manifest, and these changes lead to 
disruption of the MMP [116]. Mitochondrial depolarization precedes caspase-3 
activation and apoptosis [107], and apoptotic cells express high caspase-3 activity [56, 
147]. Caspase-3 is considered to be a primary executioner of apoptosis [10]. 
Caspase-3 activation has been causally related to the release of mitochondrial 
cytochrome c in the cytoplasm as a result of the collapse of the MMP [76]. As2O3 is 
known to act at several points in apoptosis induced through mitochondrial pathways 
[19], which includes the forming of reversible bonds with thiol groups [118] and the 
depletion of GSH [18, 66, 93, 138], loss of MMP [58], and activation of caspase-3 [28, 
58, 59, 83, 96].  
From these points of view, the apoptosis-inducing effects of As2O3 in the 
presence of GSH modulators in MOLT-4 and MOLT-4/DNR cells were examined in 
Chapter 2. 
It has been recognized that benefit and risk of arsenic are strictly dependent on 
the individual chemical forms of arsenic instead of arsenic content alone [17]. 
Although As2O3 has been confirmed to be an effective treatment for APL [42, 127], 
which acts through a variety of mechanisms involving numerous signal transduction 
pathways, and its cellular effects were mediated through apoptosis induction, growth 
inhibition and differentiation induction [6, 64, 88]. However, serious adverse drug 
reaction induced by As2O3 was occasionally reported, which deters some physicians 
from using it clinically [27].   
Arsenic disulfide (As2S2), the most important component of Xiong huang which 
contains > 90% As2S2 based on the quality standard in Chinese Pharmacopeia in 2010 
edition, was a candidate for its good therapeutic reputation and perceived low toxicity 
in traditional medicines, and the drug may become another research focus following 
As2O3. Actually, the clinical use of arsenic-containing formulae to treat malignant 
hematologic diseases in China occurred as early as the beginning of medical use of 
As2O3 [54]. Especially, the famous traditional arsenic-containing formula, Qinghuang 
Powder (QHP), which includes Qing Dai (Indigo naturalis) and Xiong huang in the 
formula, was reported to improve the clinical outcomes of hematologic malignancies 
in our clinical trials [49], and its therapeutic efficacy could be enhanced by increasing 
the Xiong huang content in the formula [145], which could be attributed to As2S2. 
Some patients treated with these regents have been reported to survive for 9-20 years 
with relatively good oral safety profiles [126]. These give As2S2 an advantage over 
As2O3 in maintenance treatment. Many results indicated that As2O3 induces apoptosis 
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in tumor cells by affecting the mitochondria and generation of reactive oxygen species 
[36, 40, 29, 63]. Mitogen activated protein kinases (MAPKs) are a family of enzymes 
that transduce signals from the cell membrane to the nucleus in response to a wide 
range of stimuli, and modulate several important biological functions including gene 
expression, mitosis, proliferation, motility, and apoptosis. Three major groups of 
MAPKs exist, the extracellular signal–regulated kinase, c-jun NH2-terminal kinase, 
and p38 MAPK families [98]. Roles of p38 MAPK in relation to reactive oxygen 
species (ROS) generation, GSH level and apoptosis induced by As2O3 have been 
demonstrated [40, 29, 63]. As2S2-mediated growth inhibition and apoptosis induction 
have been found in leukemia K562 cells [73], human ovarian and cervical cancer cells 
[132], and other cells [120]. However, the effects of As2S2 on HL-60 cells with a 
particular focus on proliferation, differentiation, oxidative stress associated with 
generation of reactive ROS and intracellular GSH depletion, and activation of p38 
MAPK have not been addressed.  
Thus, in Chapter 3, the effects of As2S2 on HL-60 cells were investigated by 
focusing on proliferation, differentiation, generation of ROS, intracellular GSH 
depletion, and activation of p38 MAPK.  
Patients with AML from myelodysplastic syndrome (MDS/AML) have higher 
probabilities of multidrug resistance to chemotherapy, lower rates of complete 
remission, and the poor prognosis [71]. Univariate analyses showed that the 
hemoglobin level and cytogenetic abnormalities were factors that contributed to the 
overall survival [68]. The data have shown that MDS/AML patients tended to have 
complex type abnormalities including monosomy-7, which is considered to be an 
unfavorable risk subgroup [34, 68]. In our recent clinical trials, we have revealed that 
QHP is effective in the treatment of MDS, especially in patients with the erythroid 
improvement is significant, without serious adverse drug reaction observed even on 
long time [133-135]. Furthermore, a high responding rate (80.8%) was also observed 
in patients with blast cell-decrease and hematologic improvement having moderate- 
and high-risks, by increasing the daily dose of QHP [74]. These results indicated that 
QHP is effective in treating MDS or MDS/AML even in patients with the poor 
karyotype, and its therapeutic efficacy could be enhanced by increasing the Xiong 
huang content in the formula, which could be attributed to As2S2. F-36p cell line was 
established from a patient diagnosed as refractory anemia with excess blasts, the 
disease progressed to overt leukemia at approximately 5 months after the initial 
diagnosis [15]. The majority of the established cells had a homogeneous karyotype. 
F-36p cells can be induced to differentiate into the erythroid lineage in the presence of 
erythropoietin.  
Thus, in Chapter 4, the effective mechanisms of As2S2 in the treatment of MDS 
or MDS/AML were studied using F-36p cell line.  
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Chapter 1 
Arsenic trioxide induces apoptosis equally in T lymphoblastoid leukemia  
MOLT-4 cells and P-gp-expressing daunorubicin-resistant MOLT-4 cells 
 
1.1 INTRODUCTION 
As2O3 has recently been confirmed to be an effective treatment for APL both in 
patients with newly diagnosed APL and in those with refractory and relapsed APL [42, 
43, 91, 109, 112, 115, 142]. The effects of As2O3 have been shown not only in 
parental APL NB4 cells [14], but also in retinoic acid-resistant APL cells [9].      
MOLT-4, a human T-lymphoblastoid leukemia cell line, has been used 
extensively for studies of leukemia cell biology and antileukemia therapy [4, 25]. A 
daunorubicin resistant MOLT-4 subline, MOLT-4/DNR, has been established by 
exposing the parental MOLT-4 cells stepwise to increasing concentrations of DNR 
over 3 months [77]. MOLT-4/DNR cells have been shown to overexpress functional 
P-gp and MDR1 mRNA [77].  
In this Chapter, the effects of As2O3 on the growth of and apoptosis in parental 
MOLT-4 and resistant MOLT-4/DNR cells were investigated, and the possible 
mechanisms of growth suppression by As2O3 in these cell lines were discussed. 
 
1.2 MATERIALS AND METHODS   
 
1.2.1 Reagents 
RPMI-1640 medium and fetal bovine serum (FBS) were purchased from Gibco 
BRL (Grand Island, N.Y.). Cell proliferation kits I and II (MTT) were purchased from 
Roche Diagnostics (Indianapolis, Ind.). Trypan blue, Rh123, DNR and As2O3 were 
obtained from Sigma Chemical Company (St. Louis, Mo.). DNR stock solutions were 
made at a concentration of 10 mmol/l with ethanol and diluted to working 
concentrations before use. As2O3 stock solutions were made at a concentration of 5 
mmol/l with phosphate-buffered saline (PBS) and diluted to working concentrations 
before use. Mouse anti-human P-gp monoclonal antibody conjugated with 
Rphycoerythrin (R-PE) (monoclonal antibody 17F9) and R-PEconjugated mouse 
IgG2b isotype control monoclonal antibody were obtained from PharMingen (San 
Diego, Calif.). The annexin V-FITC apoptosis detection kit I was obtained from BD 
PharMingen. 
 
1.2.2 Cell culture 
    MOLT-4 and MOLT-4/DNR cells were maintained in RPMI-1640 medium 
containing 10% FBS, 100 U/ml penicillin and 100 μg/mL streptomycin as described 
previously [37, 38]. The leukemia cells were washed and resuspended with the above 
medium to 5 × 105 cells/mL, then 196 μl of the cell suspension was placed in each 
well of a 96-well flat-bottomed plate. To the suspension in each well was added 4 μl 
PBS solution containing As2O3 and 4 μl ethanol solution containing DNR to yield 
final concentrations of 0.25, 0.5, 1, 2, 4, 5, 6, 8 and 16 μmol/l and 0.001, 0.01, 0.1, 1 
and 10 μM, respectively; 4 μl PBS and 4 μl ethanol were added to the control wells, 
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respectively. The cells were incubated for 96 h in an atmosphere of air containing 5% 
CO2 at 37 °C in a humidified chamber. 
 
1.2.3 MTT assay 
After the incubation period, 10 μl of MTT labeling reagent (final concentration 
0.5 mg/mL) was added to each well and the plate was placed on a microshaker for 10 
s, after which the cells were further incubated for 4 h in a humidified atmosphere. 
Subsequently, 100 μl of solubilization solution (Roche) was added to each well and 
the plate was placed on a microshaker for 10 s, after which the plate was left 
overnight in an incubator in a humidified atmosphere. The spectrophotometric 
absorbance of the samples was measured on a microplate reader (Corona MT P-32; 
Corona Company, Japan) at 570 nm. A dose response curve was plotted for each drug, 
and the concentrations that yielded a 50% inhibition of cell growth (IC50) were 
calculated. 
 
1.2.4 Cell viability assay  
MOLT-4 and MOLT-4/DNR cell lines were cultured by initially seeding 2 × 105 
cells/mL of fresh RPMI-1640 medium containing 10% FBS, 100 U/mL penicillin and 
100 μg/mL streptomycin in the presence of various concentrations of As2O3 for 24 to 
144 h in an atmosphere of air containing 5% CO2 at 37 °C in a humidified chamber. 
To avoid any possible effects of cell density on cell growth and survival, cells were 
maintained at less than 5 × 105 cells/mL by daily adjusting the cell concentration by 
adding fresh culture medium and the corresponding concentrations of As2O3 when 
necessary. The number or percentage of viable cells was determined by staining the 
cell populations with trypan blue. Before carrying out the experiments, four parts of 
0.2% trypan blue (w/v in water) were mixed with one part of saline (4.25% NaCl w/v 
in water), and one part of the trypan blue saline solution was added to one part of the 
cell suspension. The cells were then loaded into a hemocytometer and the number of 
unstained (viable) cells and stained (dead) cells were counted separately within 3 min 
of staining with trypan blue. Actual cell numbers were calculated by multiplying the 
initial cell numbers by the times dilution.  
 
1.2.5 Morphological changes in As2O3-treated MOLT-4 and MOLT-4/DNR cells  
MOLT-4 and MOLT-4/DNR cells suspended at 5 × 105 cells/mL in fresh 
medium were cultured in the presence or absence of As2O3 for 24 to 144 h in an 
atmosphere of air containing 5% CO2 at 37 °C in a humidified chamber. At the 
indicated times, pictures were taken under a microscope (Olympus Optical Company, 
Japan). 
 
1.2.6 P-gp expression analysis 
MOLT-4 and MOLT-4/DNR cells suspended at 1 × 106 cells/mL in fresh 
medium were cultured in the presence or absence of As2O3 for 3 to 24 h in an 
atmosphere of air containing 5% CO2 at 37 °C in a humidified chamber. At the 
indicated times, the cells were collected and washed twice in washing buffer 
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(PBS/0.1% NaN3, pH 7.2). Cells were resuspended in 50 μl buffer and then incubated 
with either 20 μl of monoclonal antibody 17F9 or 20 μl of the R-PEconjugated mouse 
IgG2b isotype control monoclonal antibody for 30 min in the dark. The cells were 
then centrifuged again in washing buffer (PBS/0.1% NaN3, pH 7.2) at 1300 rpm for 5 
min at 4 °C. The cells were resuspended in 400 μl staining buffer (PBS/ 0.1% 
NaN3/1% FBS, pH 7.2) and P-gp expression was determined by flow cytometry 
(Becton Dickinson). The data were analyzed with Cell Quest software (Becton 
Dickinson). 
 
1.2.7 P-gp efflux function 
Cells (1 × 106) were collected and centrifuged at 1300 rpm for 5 min at 4 °C, 
resuspended in buffer containing 5 μg/mL of Rh 123, and left to stand for 10 min in 
an atmosphere of air containing 5% CO2 at 37 °C. After washing, the cells were 
incubated in the presence or absence of As2O3 or inhibitor cyclosporine A for the 
indicated times in an atmosphere of air containing 5% CO2 at 37 °C. After incubation, 
the cells were washed twice in washing buffer and resuspended in 400 μl staining 
buffer. The remaining intracellular Rh 123 fluorescence intensity was determined by a 
flow cytometry (Becton Dickinson). The data were analyzed with Cell Quest software 
(Becton Dickinson). 
 
1.2.8 Apoptosis assays 
MOLT-4 and MOLT-4/DNR cells (1 × 106/mL) were treated with the indicated 
concentrations of As2O3. After the indicated incubation times, cells were washed 
twice in cold PBS (pH 7.2) and resuspended in binding buffer at a density of 1 × 106 
cells/mL, and then 1 × 105 cells were stained with 5 μl annexin V-FITC and 5 μl 
propidium iodide (Becton Dickinson) for 15 min at room temperature in the dark. 
Then 400 μl binding buffer was added to each tube, and the cells were analyzed by 
flow cytometry (Becton Dickinson) within 1 h of staining. A total of 30,000 
non-gated cells were analyzed. 
 
1.2.9 Statistics 
Comparison of the data between two groups was carried out using Student’s 
t-test. Comparison of the data among multiple (more than three) groups was carried 
out using the Bonferroni-Dun multiple comparison. A value of p<0.05 was considered 
significant. 
 
1.3 RESULTS  
 
1.3.1 Effects of As2O3 on parental MOLT-4 and resistant MOLT-4/ DNR cell 
growth 
MOLT-4 and MOLT-4/DNR cells were continuously treated with As2O3 at 
concentrations in the range 0.25 to 16.0 μM for 96 h, and cell growth was measured in 
an MTT assay. The growth of MOLT-4 and MOLT-4/ DNR cells was suppressed by 
As2O3 treatment in a dose- dependent manner. The IC50 values in the parental and 
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subline cells were 5.1 μM and 5.0 μM, respectively (Fig. 1-1a). 
At the same time, the viability of MOLT-4 and MOLT-4/DNR cells similarly 
decreased when the cells were incubated in the presence of As2O3 at a concentration 
of 5 μM for 24 to 144 h in a time-dependent manner (Fig. 1-2a). Following treatment 
with As2O3 for 4 days at concentrations of 1 to 16 μM, the viability of cells of both 
lines decreased to a similar extent in a dose-dependent manner (Fig. 1-2b). 
The effects of DNR on the growth of MOLT-4 and MOLT-4/DNR cells were 
examined after 96 h in culture. The IC50 value of DNR in MOLT-4 cells assessed by 
the MTT assay was 0.1 μM, while in MOLT-4/ DNR cells the value was 12 times 
higher (1.2 μM) (Fig. 1-1b). Thus, DNR was effective against parental MOLT-4 cells, 
but less effective against MOLT-4/DNR cells, as expected. 
Fig. 1-1 Comparative effects of As2O3 (a) and DNR (b) on in vitro growth of MOLT-4 and 
MOLT-4/DNR cells. Cells were treated with different concentrations of As2O3 and DNR for 4 
days. Cell growth was determined by an MTT assay. Values are the means of three independent 
experiments. 
 
Fig. 1-2 Comparison of viabilities of cells treated with As2O3 as a function of culture days (a) 
and concentration of As2O3 (b) between MOLT-4 and MOLT-4/DNR cells. a: cells treated 
with 5 μM of As2O3, b: cells treated with the agent for 4 days. Cell viability was determined by a 
dye exclusion test. Values are the means of three independent experiments 
 
1.3.2 Additive effect of As2O3 with DNR on MOLT-4/DNR cell growth 
As described above, MOLT-4/DNR cells were less sensitive to DNR alone at 
concentrations < 0.1 μM, but when MOLT-4/DNR cells were cultured in the presence 
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of DNR combined with As2O3 at 2 μM, their growth was inhibited (Fig. 1-3a). The 
suppressive effects of As2O3 and DNR appeared to be additive, and depended on the 
dose of DNR (Fig. 1-3a). 
As described above, the effects of As2O3 on the growth of MOLT-4/ DNR cells 
were observed at As2O3 concentrations > 2 μM (Fig. 1-1a, Fig. 1-2b). However, when 
the cells were treated with As2O3 at concentrations in the range 0.25 to 2 μM 
combined with 0.1 μM DNR, the effect of As2O3 on cell growth was additively 
increased (Fig. 1-3b). 
 
Fig. 1-3 Additive effect of DNR and As2O3 on the growth of MOLT-4/DNR cells. a: DNR 
concentrations varied, while As2O3 concentration was kept to be constant at 2 μM. b: As2O3 
concentrations varied, while DNR concentration was kept to be constant at 0.1 μM DNR. Cells 
were treated for 4 days. Cell growth was determined by an MTT assay. Values are the means of 
three independent experiments 
 
1.3.3 As2O3 did not change the P-gp expression and function of MOLT-4/ DNR 
cells  
Staining of cells with FITC-conjugated mouse anti-human MDR monoclonal 
antibody revealed that only 2.5% of MOLT-4 cells expressed P-gp, whereas 93.7% of 
MOLT-4/DNR cells expressed P-gp (Fig.1- 4a). To evaluate the P-gp efflux function, 
5μg/mL Rh123 as a P-gp substrate and 100ng/mL cyclosporine A as an MDR 
modulator were used in the P-gp efflux function experiments. MOLT-4/DNR cells 
incubated for 3 h in the absence of cyclosporine A showed a rapid decrease in 
intercellular Rh123 levels from 87.1 ± 0.6% to 53.3 ± 8.8% (p<0.01). The efflux was 
inhibited by cyclosporine A, and the intracellular Rh123 levels increased again to 
76.6±1.2% (p<0.05) in the presence of 100 ng/mL cyclosporine A. In contrast, 
parental MOLT-4 cells still retained the dye (from 80.4 ± 3.6% to 80.8 ± 7.8%).  
This result showed that MOLT-4/DNR cells possess a high level of P-gp efflux 
activity (Fig. 1-4b). 
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Fig. 1-4 Comparison of P-gp expression (a) and function (b) between MOLT-4 and 
MOLT-4/DNR cells. b; Effects of P-gp inhibitor cyclosporine A at 100 ng/mL on the P-gp 
expression and efflux function of MOLT-4 and MOLT-4/DNR cells. P-gp expression and function 
were determined by flow cytometry as described in Materials and methods. Values are the means 
± SD of three independent experiments. 
 
When MOLT-4/DNR cells were cultured in the presence of As2O3 at a 
concentration of 5 μM for 3 to 24 h, the percentages of P-gp expression did not 
change from those in the absence (0 h) of As2O3 (Fig. 1-5). When MOLT-4/DNR 
cells were incubated with As2O3 for 3, 6 or 24 h at concentrations of 1 to 8 μM, the 
percentage of cells expressing P-gp also did not change as compared to control (data 
not shown). 
 
 
Fig. 1-5 Effect of As2O3 on P-gp 
expression of MOLT-4/DNR cells. 
Cells were incubated in the presence 
of 5 μM As2O3 for 3, 6 and 24 h, and 
the percentages of cells expressing 
P-gp determined by flow cytometry. 
Values are the means ± SD of three 
independent experiments. 
 
 
 
 
In MOLT-4/DNR cells, intracellular Rh123 accumulation was significantly enhanced 
in the presence of cyclosporine A for 3 h at a concentration of 100 ng/mL (p<0.05, 
Fig. 1-6), but was not significantly changed in MOLT-4/DNR cells cultured in the 
presence of As2O3 at 5 μM (p>0.05. Fig. 1-6). 
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Fig. 1-6 Comparison of As2O3 and 
cyclosporine A in inhibiting P-gp 
efflux function. P-gp efflux function 
was determined by flow cytometry as 
described in Materials and Methods. 
Values are the means ± SD of three 
independent experiments. 
 
 
 
 
1.3.4 As2O3 induces apoptosis in cells of both the MOLT-4 and MOLT-4/DNR 
cell line 
MOLT-4 and MOLT-4/DNR cells showed a similar round morphology after 
culture for 96 h (Fig. 1-7a, b), but after treatment with various concentrations of 
As2O3 for 96 h, cells of both lines exhibited the typical morphological characteristics 
of apoptosis including chromatin condensation and fragmentation of nuclei (Fig. 1-7c, 
d). Numerous apoptotic bodies, which are membrane-enclosed vesicles that have 
budded off cytoplasmic extensions, were also observed in these cells (Fig.1- 7c, d). 
 
 
 
Fig. 1-7 Cell morphology 
after treatment with 5 μM 
As2O3 for 4 days. a; untreated 
MOLT-4 cells, b; untreated 
MOLT-4/DNR cells, c; As2O3- 
treated MOLT-4 cells, d; 
As2O3-treated MOLT-4/DNR 
cells 
 
 
 
 
 
 
 
In MOLT-4 and MOLT-4/DNR cells cultured in the presence of As2O3 for 4 
days at concentrations of 1 to 8 μM, the percentage of apoptotic cells as determined 
by annexin V increased in a dose-dependent manner (Fig. 1-8a), and when these cells 
were incubated with As2O3 at a concentration of 5 μM for 3 to 144 h, the percentage 
of apoptotic cells increased in a time-dependent manner (Fig. 1-8b). 
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Fig. 1-8 Induction of apoptosis by As2O3 in MOLT-4 and MOLT-4/ DNR cells. a; Percent 
apoptotic cells as a function of As2O3 concentration after culture for 4 days, b; Percent apoptotic 
cells as a function of incubation time in the presence of 5 μM As2O3. Values are the means of 
three independent experiments. 
 
1.4 DISCUSSION  
The results described above showed that As2O3 inhibited growth and induced 
apoptosis equally in MOLT-4 cells and MOLT-4/DNR cells. The results also 
suggested that the effects of As2O3 on growth of MOLT-4/DNR cells were not due to 
suppression of P-gp expression or function in these cells. 
The MOLT-4/DNR cell line was derived in our laboratory from the parental 
MOLT-4 cell line by exposing the cells stepwise to increasing concentrations of DNR 
[77], and the cell line was shown to be persistently resistant to DNR. The IC50 value 
of DNR in MOLT-4/DNR cells was 12 times higher than that in parental MOLT-4 
cells as assessed by the MTT assay. The resistance of MOLT-4/DNR cells to DNR 
has been reported to be closely correlated with the expression of functional P-gp [77]. 
MDR is recognized as one of the most common causes of failure of 
chemotherapy in the treatment of cancer patients [45, 46, 47]. P-gp is an ATP-binding 
cassette transporter, which hydrolyses ATP and expels cytotoxic drugs from 
mammalian cells [102]. The fluorescent dye Rh123 has been found to be transported 
by P-gp [22, 39, 90], and the flow cytometric measurement of cellular Rh123 
uptake/efflux is an efficient tool to assess the functional activity of P-gp in tumor 
samples [79, 80]. In this work, we revealed that 94% of MOLT-4/DNR cells express 
P-gp, and the percentage of P-gp expression in MOLT-4/DNR cells was significantly 
higher than that in MOLT-4 cells (less than 3%). Furthermore, MOLT-4/DNR cells 
exhibited significantly higher P-gp efflux activity than parental MOLT-4 cells. 
However, both parental MOLT-4 and resistant MOLT-4/DNR cell lines were highly 
sensitive to As2O3. As2O3 similarly inhibited growth and induced apoptosis in these 
two cell lines. These effects of As2O3 were time- and dose- dependent. These results 
suggest that P-gp in MOLT-4/DNR cells is not involved in the detoxification of 
As2O3. 
Indeed, the expression of P-gp in resistant MOLT-4/ DNR cells did not revert in 
the presence of As2O3 at concentrations of 1 to 8 μM, which were efficiently cytotoxic 
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for the cell line. The efflux function of P-gp in MOLT-4/DNR cells also did not 
change in the presence of various concentrations of As2O3. These observations 
confirm our conclusion that As2O3 exhibited cytotoxicity without influencing 
functional P-gp in the resistant MOLT-4/DNR cells. 
Arsenic is a natural substance that has been used medicinally for over 2400 years 
[130]. Recent clinical studies in China have shown that As2O3 is an effective and 
relatively safe drug in the treatment of APL [42, 43, 109, 142]. As2O3 can inhibit 
growth and trigger apoptosis in cells of the APL cell line NB4 [13, 14]. In particular, 
As2O3 is also effective in APL patients who are resistant to all-trans-retinoic acid 
(ATRA) and conventional chemotherapy [9, 13]. In some in vitro studies, the growth 
and survival of ATRA-resistant APL subline cells have been found to be inhibited 
effectively by As2O3 [9,14]. In addition, the suppressive effect of As2O3 is not specific 
for APL cells, but can be observed in various cell lines of myeloid [125], lymphoid 
[108, 143, 144] or T-cell origin [23, 57]. Among multiple myeloma cells, the 
P-gp-positive cell line 8226/Dox40 undergoes apoptosis in response to As2O3 in vitro, 
in a similar manner to the drug-sensitive cell line 8226/S [31]. Otherwise, 
As2O3-induced apoptosis in HL-60/VCR and HL-60/ADR cells is not significantly 
different from that in HL-60/neo cells [97]. Thus, previous results suggest that As2O3 
is not a substrate for the mdr1 gene-encoded P-gp. In this study, we demonstrated that 
As2O3 is not sensitive to drug efflux pump mechanisms of resistance. 
Studies on clinical pharmacokinetics of As2O3 have shown that the peak level of 
plasma As2O3 concentration under a general treatment schedule is 5.5 to 7.3 μM [109]. 
In the present study, the concentrations of As2O3 inducing apoptosis in vitro were 
from 1 to 8 μM in a dose- and time-dependent manner in both MOLT-4 and 
MOLT-4/DNR cells. A remarkably effective concentration of As2O3 inducing 
apoptosis in these cell lines was 5 μM, which is not over the peak level in clinical 
trials. 
Previous studies based on experiments with the APL cell line NB4 have 
indicated that As2O3 causes apoptosis directly through down- regulation of bcl-2 [13]. 
On the other hand, the GSH redox system is known to modulate the growth-inhibitory 
effect of arsenicals [18, 92]. It was found that the sensitivity to As2O3-induced 
apoptosis is inversely related to the intracellular GSH content and that 
pharmacological modulation of intracellular GSH contents influences sensitivity to 
As2O3 [18]. Thus, the effects of As2O3 in inhibiting growth and inducing apoptosis in 
the parental MOLT-4 and the resistant MOLT-4/ DNR cells may possibly be related 
to the regulation of suppressor gene (s) particularly bcl-2 and the GSH redox system. 
Since As2O3 showed no effect on P-gp expression and function in MOLT-4/DNR 
cells, the additive efficacy of As2O3 with DNR possibly results from the 
apoptosis-inducing effect of As2O3. This apoptosis- inducing effect of As2O3 is 
possibly caused by regulation of bcl-2 and/or depletion of GSH from the leukemic 
cells [13, 18, 92]. DNR is known to block DNA replication and RNA synthesis, and 
therefore, the apoptosis-inducing effect of As2O3 is possibly additive to (or synergistic 
with) the pharmacological action of DNR against the growth of MOLT-4/DNR cells. 
While P-gp may, in part, be involved in the efflux of DNR out of the cells in the 
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presence of As2O3 in MOLT- 4/DNR cells, a combination of these drugs may work 
additively through different growth-suppressing mechanisms. This additive effect can 
cause a considerable shift in the dose-response curve of each agent. These findings 
may imply potential clinical uses of DNR in combination with As2O3 for the 
treatment of patients with T-lymphoblastoid leukemia exhibiting DNR resistance. 
 
1.5 CONCLUSION  
The data in this chapter demonstrated that As2O3 is effective in suppressing 
growth and inducing apoptosis in both parental MOLT-4 cell line and its 
DNR-resistant MOLT-4/DNR cell line expressing functional P-gp. These suppressive 
effects of As2O3 are suggested not to be caused by inhibition of P-gp expression or 
function in MOLT-4/DNR cells. 
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Chapter 2 
Arsenic trioxide induces apoptosis in cells of MOLT-4 and its 
daunorubicin-resistant cell line via depletion of intracellular glutathione, 
disruption of mitochondrial membrane potential and activation of caspase-3 
 
2.1 INTRODUCTION 
In response to the observations that patients with chemorefractory APL still 
respond to As2O3 therapy [42, 109, 112] and in vitro studies of the effects of As2O3 on 
drugresistant APL cell lines [30], investigations have been initiated to evaluate the 
therapeutic potential of As2O3 in several malignant diseases [108, 143, 144]. Most of 
the reports suggest that As2O3 suppresses growth and induces apoptosis in malignant 
cells including drug-resistant cells [13, 30, 108, 143, 144]. 
As shown in Chapter 1, As2O3 is effective in growth suppression and apoptosis 
induction in both MOLT-4 and MOLT-4/DNR cells. 
Then, in this Chapter, the apoptosis- inducing mechanisms of As2O3 in MOLT-4 
and MOLT-4/DNR cell lines were investigated from the viewpoint of modification of 
cellular GSH levels, MMP, and caspase-3. 
 
2.2 MATERIALS AND METHODS 
 
2.2.1 Reagents 
   Ascorbic acid (AA), N-acetylcysteine (NAC), and L-buthionine-[S,R]-sulfoxide 
(BSO) were obtained from Sigma Chemical Company (St. Louis, Mo.). All of the 
agents were dissolved in PBS and diluted to a working concentration before use. A 
GSH assay kit was obtained from Cayman Chemical Company (Ann Arbor, Mich.). 
Metaphosphoric acid and triethanolamine were purchased from Aldrich Chemical 
Company (Milwaukee, Wis.). A PhiPhiLux-G1D2 kit was from MBL (OncoImmunin, 
Gaithersburg, Md.). Propidium iodide (PI) was from BD PharMingen. 
 
2.2.2 Cell culture 
Culture of MOLT-4 and MOLT-4/DNR cells was carried out as described in 
Chapter 1. The leukemia cells were washed and resuspended with the above medium 
to 5 × 105 cells/mL, then 196 μl cell suspension was placed in each well of a 96-well 
flat-bottom plate. PBS solutions (4 μl) containing As2O3, AA, BSO, and NAC alone 
or in combination with As2O3 with AA, BSO or NAC were added to yield the final 
indicated concentrations (see Results). PBS (4 μl) was added to the control wells. 
 
2.2.3 MTT assay 
After the incubation period, 20 μl of the MTT labeling reagent was added to each 
well to yield a final concentration of 0.5 mg/mL. Other assay procedures are same as 
those described in Chapter 1. 
 
2.2.4 Viability of cells 
MOLT-4 and MOLT-4/DNR cell lines were cultured by seeding 5 × 105 cells/mL 
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of fresh medium in the presence or absence of As2O3 alone or in combination with 
As2O3 with AA, BSO and NAC for 24-96 h in an atmosphere comprising 5% CO2/air 
at 37 oC in a humidified chamber. The number or percentage of viable cells was 
determined by staining cell populations with trypan blue, as described in Chapter 1. 
 
2.2.5 Measurement of intracellular GSH 
Cells (1 × 107) were treated for 48 h with various agents and collected by 
centrifugation at 1300 g for 10 min at 4 oC. The cells were resuspended in 500 μl of 
50 mM cold MES buffer, and then homogenized with a Handy pestle (Toyobo 
Company, Osaka, Japan) or sonicated with a Handy sonic (Tomy Seiko Company, 
Tokyo, Japan). After centrifugation at 10,000 g for 15 min at 4 oC, the supernatant was 
removed and stored on ice.  The supernatant was deproteinated with 5% MPA at 
room temperature for 5 min and centrifuged at 3000 g for 4 min. Subsequently, 50 μl 
of 4 M TEAM reagent per ml of the supernatant was added, and the solution was 
mixed immediately with a vortex mixer. The standard and samples were combined 
with fresh assay cocktail according to the manufacturer’s instructions. Samples were 
incubated in the dark on an orbital shaker before measurement. The absorbance in the 
wells was measured at 415 nm using a microplate reader. The total GSH levels were 
determined by the End Point method. 
 
2.2.6 Evaluation of MMP 
MOLT-4 and MOLT-4/DNR cells (1 × 106/mL) were treated with As2O3 alone or 
in combination with AA, BSO, or NAC. The cells were washed twice in a cold PBS 
(pH 7.2) and then incubated with 10 μg/mL Rh123 for 15 min. The cells were then 
washed twice in cold PBS, and were analyzed by flow cytometry. Living cells 
concentrate Rh123 in the mitochondria, while the MMP in cells undergoing apoptosis 
is disrupted and the mitochondria in such cells release Rh123 [39]. Therefore, the 
disruption of MMP and subsequent cell apoptosis can be detected by the decrease in 
the Rh123 fluorescence intensity in the cells. A total of 30,000 non-gated cells were 
analyzed using a FACSCalibur analyzer (Becton Dickinson, San Jose, Calif.) to obtain 
dot data. These data were further analyzed using CellQuest Software (Becton 
Dickinson). 
 
2.2.7 Assessment of caspase-3 activity 
Cells (1 × 106/mL) were treated with As2O3 alone or in combination with AA, 
BSO, or NAC. After incubation, an aliquot of cells was placed into a 1.5-ml 
microcentrifuge tube, and the cells were then centrifuged and the entire culture 
medium was removed. Subsequently, 50 μl of a substrate solution containing 10 μM 
caspase-3 substrate was added to the cell pellet, and the suspension was mixed by 
flicking the tubes with the fingertip. The substrate molecule contains a peptide 
homodoubly labeled with a fluorophore. The cleaved substrate has specific 
fluorescence peak characteristics (λex 505 nm and λem 530 nm), which can be detected 
by flow cytometry. After incubation of the tubes in 5% CO2/air at 37
 oC in a 
humidified chamber for 60 min, the cells were washed once by adding 1 ml ice-cold 
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flow cytometry dilution buffer. The cells were resuspended in 1 ml fresh dilution 
buffer for analysis by flow cytometry. All samples were analyzed within 6 min of the 
end of the 37 oC incubation. 
 
2.2.8 Apoptosis assays 
After collecting data for caspase-3 activity, 5 μl 50 μg/mL PI was added and 
samples were reanalyzed flow cytometrically according to the manufacturer’s 
instructions. The data were reanalyzed within 5 min of PI addition, and the 
caspase+/PI-) cells were considered apoptotic cells. 
 
2.2.9 Morphological changes of cells 
MOLT-4 and MOLT-4/DNR cells (5 × 105/mL) were cultured in the absence or 
presence of As2O3 alone or in combination with AA, BSO, or NAC for 72 h in an 
atmosphere comprising 5% CO2/air at 37
 oC in a humidified chamber. Pictures were 
taken under a microscope (Olympus Optical Company, Tokyo, Japan). 
 
2.2.10 Statistics 
Student’s t-test was used to compare the data between two groups, and the 
Bonferroni/Dun multiple comparison test was used to compare the data among 
multiple (more than three) groups. A value of p<0.05was considered to be significant. 
 
2. 3 RESULTS 
 
2.3.1 Effects of BSO, AA, or NAC on the growth-inhibitory action of As2O3 in 
MOLT-4 and MOLT-4/DNR cells  
After 72 h of treatment, the growth-inhibitory effects of 5 μM As2O3 on MOLT-4 
and MOLT-4/DNR cells were significantly enhanced by 100 μM BSO and 125 μM 
AA (Fig. 2-1). BSO is known to be a selective inhibitor of γ-glutamylcysteine 
synthetase, the rate-limiting enzyme in GSH synthesis [5]. The IC50 values of As2O3 
on the cell growth of MOLT-4 and MOLT-4/DNR cells were 4.8 and 5.3 μM, 
respectively (Table 2-1). Thus, BSO and AA increased sensitivity to As2O3 treatment. 
The IC50 values of As2O3 decreased significantly to less than 2 μM in the presence of 
100 μM BSO (p<0.001). The IC50 values of As2O3 in both cell lines were also 
decreased significantly (p<0.01) by the addition of AA (Table 2-1). Whereas, 100 μM 
BSO and 125 μM AA alone did not affect the growth of either MOLT-4 or 
MOLT-4/DNR cells (the IC50 values of both BSO and AA were higher than 500 μM ). 
In contrast, NAC efficiently protected both MOLT-4 and MOLT-4/DNR cells from the 
cytotoxicity of As2O3, when the two cell lines were incubated with 5 μM As2O3 in 
combination with 10 mM NAC for 72 h (Fig. 2-1). Thus, NAC made the cells of both 
the MOLT-4 and MOLT-4/DNR unresponsive to the growth-inhibitory effect of As2O3. 
The IC50 values of As2O3 in the presence of NAC in these cell lines were determined 
to be higher than 8 μM (Table 2-1). 
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Fig. 2-1 Modulation of As2O3-mediated growth inhibition of MOLT-4 (A) and 
MOLT-4/DNR (B) cells by BSO, AA, and NAC. Cells were treated with 5 μM of As2O3 in the 
absence or presence of 100 μM BSO, 125 μM AA, and 10 mM NAC for 72 h. Cell growth was 
determined by an MTT assay. Values are the means ± SD of three independent experiments. # 
p<0.05, ##p<0.001 vs control; *p<0.01 vs As2O3 alone. 
 
Table 2-1. IC50 values (μM) of As2O3 alone or in combination with BSO, AA, and NAC on 
MOLT-4 and MOLT-4/DNR cell growth.  
 
Treatment               MOLT-4         MOLT-4/DNR     
 
                                  IC50 
 
As2O3 alone              4.8 ± 0.2         5.3 ± 0.3 
As2O3+AA (125 μM)       3.5 ± 0.1**       4.3 ± 0.1* 
As2O3+BSO (100 μM)      1.2 ± 0.0**       1.1 ± 0.0** 
As2O3+NAC (10 mM)        >8              >8           
 
Cells were treated with 100 μM BSO, 125 μM AA, and 10 mM NAC in presence or absence of 
serial concentrations of As2O3 for 72 h, and cell growth was determined by an MTT assay. Values 
are the means ± SD of three independent experiments. *p<0.01, **p<0.001 vs As2O3 alone. 
 
 
Similarly, the viability of MOLT-4 and MOLT-4/DNR cells was significantly 
decreased following incubation for 72 h with 5 μM As2O3 plus 100 μM BSO or 125 
μM AA, as compared to cells treated with As2O3 alone (P<0.001, Fig. 2-2). In contrast, 
10 mM NAC markedly increased the viability of these cells under the same culture 
conditions (p<0.001, Fig. 2-2). 
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Fig. 2-2 Modulation of As2O3-mediated reduction in viability of MOLT-4 (A) and 
MOLT-4/DNR (B) cells by BSO, AA, and NAC. Cells were incubated in the absence or 
presence of 5 μM As2O3 in the absence or presence of 100 μM BSO, 125 μM AA, or 10 mM 
NAC for 72 h. Cell viability was determined by a dye exclusion test. Values are the means ± 
SD of three independent experiments.  # p<0.001 vs control; *p<0.001 vs As2O3 alone. 
 
2.3.2 Intracellular GSH content modulated by BSO, AA, or NAC in MOLT-4 and 
MOLT-4/DNR cells 
The GSH contents of MOLT-4 and MOLT-4/DNR cells were 105.0 ± 1.6 and 
105.6 ± 2.4 μM/107 cells, respectively, when the two cell lines were incubated in the 
absence of the modulating agents for 48 h. Thus, the intracellular GSH contents of 
MOLT-4 and MOLT-4/DNR cells were at the same level. 
MOLT-4 and MOLT-4/DNR cells were incubated in the absence or presence of 
100 μM BSO, 125 μM AA or 10 mM NAC for 48 h. These treatments resulted in 
significant changes in GSH content (Fig. 2-3). BSO decreased the GSH content to a 
greater extent (p<0.01), and AA also significantly decreased GSH level (p<0.05) in 
both MOLT-4 (Fig. 2-3A) and MOLT-4/DNR (Fig. 2-3B) cells. Whereas, NAC 
significantly increased the GSH content (p<0.05) in these cells. 
Fig. 2-3 Modulation of intracellular GSH levels by BSO, AA, and NAC in MOLT-4 (A) and 
MOLT-4/DNR (B) cells. Cells were incubated in the absence or presence of 100 μM BSO, 125 
μM AA, or 10 mM NAC for 48 h. GSH levels were measured using a GSH assay kit as described 
in Materials and Methods. Values are the means ± SD of three independent experiments carried 
out in triplicate. *p<0.05, **p<0.01 vs basal level. 
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2.3.3 Disruption of MMP in MOLT-4 and MOLT-4/DNR cells 
The disruption of MMP by As2O3 and its modulation by AA, BSO or NAC are 
presented in Figs. 2-4 and 2-5. In each histogram, the percentage of cells with 
decreased MMP is indicated. The disruption of MMP in MOLT-4 (Figs. 2-4A and 
2-5A) and MOLT-4/DNR (Figs. 2-4B and 2-5B) cells was significantly higher 
(p<0.01) after 72 h treatment with 5 μM As2O3 than in untreated cells. This 
As2O3-induced disruption of MMP was markedly enhanced by AA (p<0.01) and BSO 
(p<0.001) in both MOLT-4 (Fig. 2-5A) and MOLT-4/DNR (Fig. 2-5B) cells (Figs. 
2-4Ac,d, Bc,d). In particular, BSO elevated this ability almost completely (Fig. 2-5), 
while the As2O3-induced disruption of MMP was blocked by NAC in these cells (Figs. 
2-4Ad,e, Bd,e, and Fig. 2-5). In contrast, 125 μM AA, 100 μM BSO and 10 mM NAC 
treatment alone did not influence the MMP of these cells (data not shown). 
 
Fig. 2-4 Typical histograms 
showing the disruption of 
MMP in MOLT-4 cells (A) 
and MOLT-4/DNR cells (B) 
incubated for 72 h in the 
absence (a) or presence of 5 
μM As2O3 alone (b) or with 
a combination of 5 μM 
As2O3 and 125 μM AA (c), 
100 μM BSO (d), or 10 mM 
NAC (e). The percentage 
given in each histogram is the 
percentage of cells with 
decreased MMP. 
 
 
 
   
Fig. 2-5 MMP disruption in MOLT-4 cells (A) and MOLT-4/DNR cells (B) treated with 5 
μM As2O3 alone or with a combination of 5 μMAs2O3 and 125 μM AA, 100 μM BSO, or 10 
mMNAC for 72 h. Values are the means ± SD of three independent experiments. # p<0.01 vs 
control; *p<0.01, **p<0.001 vs As2O3 alone. 
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2.3.4 Activation of caspase-3 in MOLT-4 and MOLT-4/DNR cells 
The activation of caspase-3 by As2O3 and its modulation by AA, BSO or NAC is 
presented in Figs. 2-6 and 2-7.  In each histogram in Fig. 2-6, the percentage of cells 
expressing relatively high activity of caspase-3 is indicated. After 72 h of treatment, 5 
μM As2O3 significantly induced caspase-3 activity in MOLT-4 (p<0.01) (Fig. 2-7A) 
and MOLT-4/DNR (p<0.01) (Fig. 2-7B) cells (Fig. 2-6). This activation of caspase-3 
was markedly potentiated by AA (p<0.001) and BSO (p<0.001) in both MOLT-4 (Fig. 
2-7A) and MOLT-4/DNR (Fig. 2-7B) cells (Figs. 2-6Ac,d, Bc,d). In particular, BSO 
elevated the levels of caspase-3 activity to a greater extent, whereas the enzyme 
activation by As2O3 was completely attenuated by NAC in both MOLT-4 (p<0.01) 
(Fig. 2-7A) and MOLT-4/DNR (p<0.001) (Fig. 2-7B) cells (Figs. 2-6Ae, Be). In 
contrast, 125 μM AA, 100 μM BSO and 10 mM NAC treatment alone did not 
modulate the caspase-3 activity of these cells (data not shown). 
 
Fig. 2-6 Typical histograms showing the 
changes in percentage of MOLT-4 cells 
(A) and MOLT-4/DNR cells (B) 
exhibiting caspase-3 activity following 
treatment for 72 h in the absence (a) or 
presence of 5 μMAs2O3 alone (b) or with 
a combination of 5 μM As2O3 and 125 
μM AA (c), 100 μM BSO (d), or 10 mM 
NAC (e). The percentage given in each 
histogram is the percentage of cells with 
caspase-3 activity. 
 
 
 
 
 
   
Fig. 2-7 Changes in caspase-3 activity after treating MOLT-4 cells (A) and MOLT-4/DNR 
cells (B) for 72 h with 5 μM As2O3 alone or with a combination of 5 μM As2O3 and 125 μM 
AA, 100 μM BSO, or 10 mM NAC. Values are the means ± SD of three independent experiments. 
# p<0.05 vs control; *p<0.01, **p<0.001 vs As2O3 alone. 
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2.3.5 Modulation of As2O3-induced apoptosis by AA, BSO, or NAC in MOLT-4 
and MOLT-4/DNR cells 
As2O3-induced apoptosis and its modulation by AA, BSO or NAC are presented 
in Figs. 2-8 and 2-9. The dots in the upper left quadrant are those of caspase+/PI- cells 
indicating apoptotic cells. In each dot plot the percentage of apoptotic cells is 
indicated.  In these experiments, the cells were treated in the absence or presence of 
5 μM As2O3 alone or in combination with 100 μM BSO, 125 μM AA or 10 mM NAC. 
5 μM As2O3 treatment alone induced apoptosis in both MOLT-4 (p<0.01) (Fig. 2-9A) 
and MOLT-4/DNR cells (p<0.001) (Fig. 2-9B) as compared to the control cells (Figs. 
2-8Aa,b, Ba,b). BSO and AA significantly (P<0.001) increased the percentage of 
apoptotic cells induced by As2O3 in both MOLT-4 (Fig. 2-9A) and MOLT-4/DNR 
cells (Figs. 2-9B, 2-8Ac,d, and 2-8Bc,d), whereas NAC markedly decreased the 
percentage of apoptotic cells induced by As2O3 in both MOLT-4 (p<0.001, Fig. 2-9A) 
and MOLT-4/DNR (p<0.01) (Fig. 2-9B) cells (Fig. 2-8Ae, Be). Cells treated with 100 
μM BSO, 125 μM AA or 10 mM NAC alone did not show increase in the percentage 
of apoptotic cells (data not shown). 
 
Fig. 2-8 Typical dot plots 
showing apoptotic MOLT-4 
cells (A) and MOLT-4/DNR 
cells (B) following incubation 
for 72 h in the absence (a) or 
presence of 5 μM As2O3 alone (b) 
or with a combination of 5 μM 
As2O3 and 125μM AA (c), 100 
μM BSO (d), or 10 mM NAC (e).  
The percentage given in each dot 
plot is the percentage of apoptotic 
cells. The dots in the upper left 
quadrant are caspase+/ PI- cells 
indicating apoptotic cells 
(abscissa PI-related intensity, 
ordinate caspase activity-related 
intensity). 
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Fig. 2-9 As2O3-induced apoptosis and its modulation by BSO, AA, or NAC in MOLT-4 cells 
(A) and MOLT-4/DNR cells (B) treated with 5 μM As2O3 alone or with a combination of 5 
μM As2O3 with 125 μM AA, 100 μM BSO, or 10 mM NAC for 72 h. Values are the means ± SD 
of three independent experiments. # p<0.01, ## p<0.001 vs control; *p<0.01, **p<0.001 vs As2O3 
alone. 
 
BSO and AA potentiated the apoptotic morphology induced by As2O3 in 
MOLT-4 (Figs. 2-10Ac, d) and MOLT-4/DNR (Figs. 2-10Bc, d) cells. Whereas, NAC 
markedly restored a normal morphology to MOLT-4 (Fig. 2-10Ae) and MOLT-4/DNR 
(Fig. 2-10Be) cells treated with As2O3, in comparison to those treated with As2O3 
alone (Fig. 2-10Ab, Bb). 
 
 
Fig. 2-10 Morphology of 
MOLT-4 cells (A) and 
MOLT-4/DNR cells (B) 
after treatment with 5 μM 
As2O3 alone or with 
combination of 5 μM 
As2O3 and 100 μM BSO, 
125 μM AA, or 10 mM 
NAC for 72 h. a; untreated 
cells, b; cells treated with 5 
μM As2O3 alone, c; cells 
treated with 5 μM As2O3 
combined with 125 μM AA, 
d; cells treated with 5 μM 
As2O3 combined with 100 
μM BSO, e; cells treated 
with 5 μM As2O3 combined 
with 10 mM NAC. 
 
 
 
 
28 
 
2.4 DISCUSSION 
 
2.4.1 GSH content had a decisive effect on As2O3-mediated cytotoxicity 
The data in Chapter 1 showed that the effects of As2O3 on the growth of 
MOLT-4/DNR cells are the same as its effects on parental MOLT-4 cells, and the 
actions of As2O3 do not influence their P-gp expression or function [44]. The data  in 
this chapter indicated that the intracellular GSH levels in parental MOLT-4 and 
MOLT-4/DNR cells are almost the same. A reduction in GSH levels following 
incubation with BSO and AA enhanced the As2O3-mediated inhibition of cell growth, 
disruption of MMP, activation of caspase-3 and apoptosis in MOLT-4 cells and 
MOLT-4/DNR cells. Whereas, NAC elevated the intracellular GSH levels and 
protected the cells from the cytotoxicity of As2O3. These observations suggested that 
the sensitivity of both MOLT-4 and MOLT-4/DNR cells to As2O3 is closely correlated 
with intracellular GSH levels. 
GSH is a low molecular weight, non-protein, sulfhydryl compound and its role in 
the protection of cells from oxidative injury has been documented in a study that 
demonstrated the enhancement of damage by depletion of cellular GSH [92]. GSH 
exerts antioxidant effects and it can conjugate with and thereby inactivate molecules 
that generate free radicals. Trivalent arsenic has been reported to form a complex with 
GSH, forming a transient As(GS)3 molecule [118], which is easily excreted by the 
MRP2/cMOAT transporter [62]. Thus, GSH maintains an optimum cellular redox 
potential, and depletion, physical efflux from the cell, or intracellular redistribution of 
GSH are associated with the onset of apoptosis [16].  
BSO is a selective inhibitor of γ -glutamylcysteine synthetase, the 
rate-limiting enzyme in the synthesis of GSH. Cells incubated with BSO are depleted 
of GSH as a result of the inhibition of enzymatic GSH production [92]. AA has been 
shown to have pro-oxidant properties [6, 103]. Auto-oxidation of AA to 
dehydroascorbate results in the production of H2O2 [106, 119]. Dehydroascorbate is 
then rapidly reduced back to AA by glutaredoxin in a GSH-dependent manner. This 
reduction of dehydroascorbate to AA results in a decrease in intracellular GSH [122, 
129]. Clinically relevant doses of AA act as oxidizing agents decreasing the GSH 
content of the cells, and synergizes with the growth-inhibitory and apoptosis-inducing 
effects of As2O3. This potentiating effect of AA is due to its capacity to undergo 
auto-oxidation resulting in the formation of H2O2, which enhances the effects of 
As2O3 [31]. Indeed, it has been found that AA significantly synergizes with As2O3 in 
treating patients with AML [5].  NAC is an antioxidant since it donates a cysteine to 
the de novo synthesis of GSH. As2O3 has been reported to bind to vicinal thiol groups 
[128], while NAC contains two such thiol groups [31] and gives GSH. Taking these 
observations into consideration, the decrease in GSH levels following incubation with 
BSO and AA could abate As2O3 exclusion, thereby causing an intracellular 
accumulation of As2O3 and enhancing its cytotoxicity. In contrast, the increase in 
intracellular GSH levels following incubation with NAC could enhance As2O3 
exclusion, and thereby attenuate the toxic effects of As2O3. 
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2.4.2 As2O3-induced apoptosis via depletion of GSH, loss of MMP and activation 
of caspase-3 
Intracellular GSH depletion results in morphological and functional changes of 
mitochondria [110]. It has been found that the changes of mitochondria after treatment 
with As2O3 can be divided into three stages [110]. In the early stage, mitochondria 
appear to undergo an adaptive proliferation. In the middle stage, a degenerative 
change can be observed. In the late stage, the mitochondria swell, and this change is 
followed by damage to the outer membrane and cell death which exhibits apoptotic 
changes to the nucleus. Mitochondria are known to play a major role in apoptosis 
triggered by many stimuli [20]. In the first stage of apoptosis, signal transduction 
cascades or damage pathways are activated. Subsequently, the mitochondrial 
membrane function is lost, and then proteins released from mitochondria cause the 
activation of catabolic proteases and nucleases [106]. Caspases are cysteine proteases 
that mediate apoptosis by proteolysis of specific substrates [65]. Caspase-3 is 
considered to be a primary executioner of apoptosis [107]. The data in this Chapter 
showed that the disruption of MMP and activation of caspase-3 are caused by As2O3, 
and are enhanced by AA and BSO, while blocked by NAC, in both MOLT-4 and 
MOLT-4/DNR cells. The extent of MMP disruption and caspase-3 activation are 
closely associated with intracellular GSH levels and occur in a time-dependent 
manner. 
Recent reports suggest that sensitivity to As2O3 correlates with intracellular GSH 
levels in cancer cells [138]. The GSH content modulates the growth-inhibitory and 
apoptosis-inducing effects of arsenicals [18, 60, 92, 93, 105]. Cells expressing higher 
levels of GSH or GSH-associated enzymes are less sensitive to As2O3 than cells 
expressing lower levels of these molecules [60, 72]. Arsenic- resistant cells are also 
reported to contain higher levels of GSH [66, 72, 78]. Moreover, cells with increased 
GSH levels can be sensitized to As2O3 by agents that deplete intracellular GSH [18, 
66]. The cytotoxic effects of As2O3 may be influenced by modulators of GSH [31, 33, 
67, 89], especially in drug-resistant cell lines [28, 100]. 
A decrease in GSH level in cells acts as a potent early activator of apoptosis 
signaling [3]. Depletion of GSH, especially mitochondrial GSH, is believed to induce 
the loss of MMP [84]. In my present study, the GSH content significantly decreased  
in both MOLT-4 (Fig. 2-3A) and MOLT-4/DNR (Fig. 2-3B) cells incubated with BSO 
and AA for 48 h. As2O3-induced disruption of MMP was markedly enhanced by AA 
and BSO in both MOLT-4 (Fig. 2-5A) and MOLT-4/DNR (Fig. 2-5B) cells (Figs. 
2-4Ac,d, Bc,d) incubated with BSO and AA for 72 h. The percentage of apoptotic 
cells induced by As2O3 significantly increased in both MOLT-4 (Fig. 2-9A) and 
MOLT-4/DNR cells (Figs. 2-9B, 2-8Ac,d, and 2-8Bc,d ) incubated with BSO and AA 
for 72 h, Whereas, NAC significantly increased the GSH content, and the 
As2O3-induced disruption of MMP and apoptosis were blocked by NAC in these cells. 
Mitochondrial permeability transition resulting from intracellular thiol depletion 
is known to be a critical event in apoptosis [75, 136]. Mitochondria undergo major 
changes in membrane integrity before classical signs of apoptosis become manifest, 
and these changes lead to disruption of the MMP [116]. These alterations in 
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mitochondrial activity can be distinguished and monitored by the fluorescent dye 
Rh123 on flow cytometry [106, 119], which specifically stains mitochondria 
depending on the MMP [70, 94, 101]. Mitochondrial depolarization precedes 
caspase-3 activation and apoptosis [107], and apoptotic cells express high caspase-3 
activity [56, 147]. Caspase-3 is considered to be a primary executioner of apoptosis 
[10, 65]. Caspase-3 activation has been causally related to the release of 
mitochondrial cytochrome c in the cytoplasm as a result of the collapse of the MMP 
[76]. 
As2O3 is suggested to act at several points in apoptosis induced through 
mitochondrial pathways [19], which includes the forming of reversible bonds with 
thiol groups [118] and the depletion of GSH [18, 66, 93, 138], loss of MMP [58], and 
activation of caspase-3 [28, 58, 59, 83, 96]. From these points of view, the apoptosis 
inducing effect of As2O3 in the presence of GSH modulators in MOLT-4 and 
MOLT-4/DNR cells was investigated in this Chapter. 
 
2.5 CONCLUSION  
In this chapter, it can be concluded that As2O3 induces apoptosis in MOLT-4 and 
MOLT-4/DNR cells via the depletion of intracellular GSH, and subsequent MMP 
disruption and caspase-3 activation, based on the following observations: 
(1) MOLT-4 cells and MOLT-4/DNR cells were similarly sensitive to the 
apoptosis-inducing effect of As2O3.  
(2) BSO and AA rendered these cells more sensitive to As2O3, whereas NAC 
reduced this sensitivity.  
(3) BSO and AA decreased, but NAC increased, the intracellular GSH contents 
of both MOLT-4 and MOLT-4/DNR cells.  
(4) Decreasing GSH with BSO or AA potentiated As2O3- mediated growth 
inhibition, disruption of MMP, activation of caspase-3 and apoptosis of cells.  
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Chapter 3 
Involvement of oxidative stress associated with glutathione depletion and p38 
MAPK activation in arsenic disulfide-induced differentiation in HL-60 cells 
 
3.1 INTRODUCTION 
As2S2, the most important component of Xiong huang (contains > 90% As2S2 
based on the quality standard in Chinese Pharmacopeia in 2010 edition), was a 
candidate for its good therapeutic reputation and perceived low toxicity, and the drug 
has become another research focus following As2O3
 [131]. As2S2 was found as 
effective as As2O3 in clinical trials, with relatively good oral safety profiles even on 
chronic administration [131, 49]. These may give As2S2 an advantage over As2O3 in 
maintenance treatment.  
As2S2-mediated growth inhibition and apoptosis induction have been found in 
leukemia K562 cells [73], human ovarian and cervical cancer cells [132], and other 
cells [120]. However, the effects of As2S2 on HL-60 cells with a particular focus on 
proliferation, differentiation, oxidative stress associated with generation of reactive 
ROS and intracellular GSH depletion, and activation of p38 MAPK have not been 
addressed.  
 
3.2 MATERIALS AND METHODS 
 
3.2.1 Reagents  
As2S2, phorbol 12-myristate 13-acetate, nitroblue tetrazolium (NBT), 
2’,7’-dichlorofluorescein diacetate (DCFH-DA), and ortho-phthaldialdehyde were 
purchased from Sigma Aldrich (St. Louis, Mo., USA). SB203580 was purchased from 
Calbiochem (San Diego, CA, USA). R-PE conjugated anti-human CD11b (Clone 
D12) and mouse IgG1 isotype control were obtained from DakoCytomation 
(DakoCytomation Denmark A/S). PE Mouse Anti-p38 MAPK (pT180/pY182) and the 
AnnexinV-FITC apoptosis detection kit I were obtained from BD PharMingen. 
Hydrogen peroxide (H2O2) and methanol were purchased from Wako (Wako Pure 
Chemical Industries, Ltd, Japan). 10% - Formaldehyde Neutral Bufferwas product of 
Nacarai Tesque (Japan). As2S2 was dissolved in 1N NaOH, and HCl was used to 
adjust the pH to 7.35-7.45. The solution was passed through a 0.20 μm filter 
(Advantec, Japan), and the stock solution was made by PBS at a concentration of 
5mM, which was diluted by PBS to working concentrations before use. DCFH-DA 
and Rhodamine 123 were dissolved in DMSO at 5 mM and 1 mg/mL, respectively, 
and stored at -20 °C. The ortho-phthaldialdehyde solution was freshly prepared in 
methanol at 10 mg/mL before use. 
 
3.2.2 Cell culture 
HL-60 cells were purchased from the American Type Culture Collection 
(ATCC) (Manassas, VA). The cells were maintained in RPMI-1640 medium 
containing 10% FBS, 100U/mL penicillin and 100μg/mL streptomycin in continuous 
logarithmic growth between 2 - 10 × 105 cells/mL at 37 °C in a humidified 5% CO 2 
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incubator.   
 
3.2.3 MTT assay 
The leukemia cells were washed and resuspended with the above medium to 5 × 
105 cells/mL, and then 196 μl of the cell suspension was placed in each well of a 
96-well flat-bottomed plate. To the suspension in each well, 4 μl PBS solution 
containing As2S2 was added to yield final concentrations of 0.5, 2, 8, and 16μM, 
respectively; 4 μl PBS was added to the control wells. The cells were incubated for 
48h in an atmosphere containing 5% CO2 at 37 
oC in a humidified chamber. After the 
incubation period, 20 μl of MTT labeling reagent (final concentration 0.5 mg/mL) 
was added to each well and the plate was placed on a microshaker for 10s, after which 
the cells were further incubated for 4 h in a humidified atmosphere. Subsequently, 
100 μl of solubilization solution (Roche) was added to each well and the plate was 
placed on a microshaker for 10s, after which the plate was left overnight in an 
incubator in a humidified atmosphere. The spectrophotometric absorbance of the 
samples was measured on a microplate reader (LS-PLATE manager 2001, Japan) at 
570 nm. A dose response curve was plotted. 
 
3.2.4  Assessment of cell differentiation 
HL-60 cells (1 × 106/mL) were treated with the indicated concentrations of As2S2. 
After the indicated incubation times, cells were washed twice by PBS containing 2% 
FBS and resuspended in 100 μl PBS containing 2% FBS. Then, 10 μl PE-conjugated 
CD11b antibody was added, and cells were incubated in the dark at 4 °C for 30 min. 
After the incubation, cells were resuspended in 400 μl PBS containing 1% FNB, and 
subsequently the cells were analyzed by Becton Dickinson flow cytometry. Isotypic 
mouse IgG1 was used to set threshold parameters. A total of 30,000 non-gated cells 
were analyzed. In case of the assessment of synergistic differentiation induced by 
H2O2 combined with As2S2, cells were pre-incubated with indicated concentration of 
H2O2 for 1 h before treatment with As2S2 for 48h. When assessment of effects of 
SB203580 on As2S2-induced differentiation, cells were incubated with indicated 
concentrations of As2S2 alone or combined with SB203580 for 72h, 0.05% DMSO 
was used as control. 
The As2S2-induced HL-60 cell differentiation was observed by morphological 
changes, which were determined by flow cytometry after treatment of As2S2 for 48h. 
Light scattering signal measured in the forward is known as forward scattering 
(forward scatter, FSC) in flow cytometry analyses, which reflects the size of the cell 
volume.  
The As2S2-induced differentiation of HL-60 cells to neutrophil-like cells was also 
assessed by NBT reduction assay [82, 123]. After HL-60 cells (1 × 106/mL) were 
treated with the indicated concentrations of As2S2 for 72 h, cells were washed by PBS, 
and then cells were suspended in 1 ml serum free RPMI-1640 medium containing 4 
mg/ml of NBT and 2 μg/mL of phorbol 12-myristate 13-acetate. After incubation at 
37 °C for 1 h, 200 μl of 6 M HCl was added and the cells chilled on ice for 30 min. 
Then the samples were centrifuged at 1,000 g for 10 min, and the formazan deposits 
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were dissolved with 600 μl DMSO. The absorbance was measured at 560 nm.  
 
3.2.5 Apoptosis and viability assays 
After HL-60 cells (1 × 106/mL) were treated with the indicated concentrations of 
As2S2 for the indicated incubation times, the cells were washed twice by cold PBS 
(pH 7.2) and resuspended in binding buffer at a density of 1 × 106 cells/mL. Then 1 × 
105 cells were stained with 5 μl Annexin V-FITC and 5 μl PI for 15 min at 4 ° C in the 
dark. Then 400 μl binding buffer was added to each tube, and the cells were analyzed 
by Becton Dickinson flow cytometry within 1 h of staining.  A total of 3 × 104 
non-gated cells were analyzed. Cell viability was determined by PI exclusion. Cell 
apoptosis was identified by positive Annexin V-staining.  
 
3.2.6 Cellular ROS production measurement 
Cellular ROS production was measured by flow cytometry using DCFH-DA [36, 
40, 63, 123]. Viable cells can deacetylate DCFH-DA to DCFH. The latter is not 
fluorescent but can react with H2O2 to produce fluorescent DCF. The cytofluorimetric 
measurement of DCF provides an index of cellular ROS level [123]. At the end of 
treatment by As2S2, cells in each well were collected, washed twice in PBS and 
incubated in 1 ml PBS containing 10 μM DCFH-DA at 37 °C for 30 min. Cells were 
then washed in PBS and resuspended in 0.5 ml PBS. The mean fluorescence intensity 
(MFI) of DCF green fluorescence from 1 × 104 cells was detected by Becton 
Dickinson flow cytometry. The ROS level in the treated cells against that of the 
control is represented by relative MFI. 
 
3.2.7 Determination of level of cellular GSH 
The temporal change in cellular GSH was evaluated using 
ortho-phthaldialdehyde [123], which can react with GSH to yield a highly fluorescent 
product. At the indicated times of cells incubated with As2S2, cells were washed twice 
by PBS and then suspended in 900 μl PBS. Then, 100μl of 10 mg/mL 
ortho-phthaldialdehyde in methanol was added, and cells were incubated at 37 °C for 
30 min. After being washed by PBS, cells were resuspended in 500 μl PBS and kept 
on ice. MFI thus produced from 1 × 104 cells was measured by Becton Dickinson 
flow cytometry. The levels of cellular GSH were represented by relative MFI. 
 
3.2.8 Analysis for p38 MAPK activation 
Activation of p38 MAPK was detected by flow cytometry [81]. Cells (1 × 
106/mL) were exposed to different concentrations of As2S2 for indicated times. The 
cells were collected by centrifugation and washed by PBS, and then fixed for 10 
minutes at 37 °C in PBS containing 2% FNB. Cells were centrifuged and resuspended 
in 90% methanol, and then incubated for 30 minutes on ice. The cells were washed 
twice by PBS and resuspended in PBS 100 μl. Subsequently, PE-labeled anti 
phosphorylated p38 MAPK antibody was added and incubated for 1 h at room 
temperature. Cells were resuspended in 400 μl PBS containing 1% FNB and analyzed 
with Becton Dickinson flow cytometry. 
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3.2.9 Western blot analysis 
Protein samples were separated on a SDS–PAGE, followed by transferring to a 
nitrocellulose membrane as described previously [140]. Protein bands were detected 
using the following primary antibodies: mouse anti-human β-actin (1:5000 dilution, 
Sigma–Aldrich, MO, USA); rabbit anti-human phospho-p38 MAPK (Thr180/Tyr182) 
(1:1000 dilution), and rabbit anti-human p38 MAPK (1:1000 dilution) (Cell Signaling 
Technology, MA, USA). Blotted protein bands were detected with respective 
horseradish peroxidase-conjugated secondary antibody and an enhanced 
chemiluminescenceWestern blot analysis system (Amersham Pharmacia Biotech, 
Buckinghamshire, UK). 
 
3.2.10 Determination of MMP 
MMP was assessed using the cationic lipophilic dye R123 [48, 36, 123, 137]. 
Cells (1 × 106/mL) were treated with different concentrations of As2S2 for indicated 
times. At the end of incubation, cells were collected and washed twice in PBS and 
incubated in 1 ml PBS containing 10 μg/ mL Rh123 at 37 °C for 30 min. Cells were 
washed with PBS and resuspended in 500 μl PBS. 3 × 104 cells were analyzed with 
Becton-Dickinson flow cytometry, and MMP is represented by relative MFI. 
 
3.2.11 Statistics 
Data were shown as the mean ± standard deviation (SD) of three independent 
experiments. Differences were estimated by one-way ANOVA. A value of p<0.05 was 
considered significant. 
 
3.3 RESULTS 
 
3.3.1 Effects of As2S2 on cell growth and differentiation 
After treatment with As2S2 at concentrations in the range of 0.5 to 16.0 μM for 
72 h, cell growth was measured in an MTT assay. As2S2 at 16 μM inhibited growth of 
HL-60 cells, while the agent at 0.5, 2, and 8 μM did not inhibit the proliferation (Fig. 
3-1). 
 
Fig. 3-1 Effects of As2S2 on in vitro 
growth of HL-60 cells. Cells were 
treated with serial concentrations of 
As2S2 for 72 h. Cell growth was 
determined by an MTT assay. Data are 
the mean ± SD of 3 independent 
experiments. 
 
CD11b, which is widely used in differentiation studies of leukemia cells [82, 123, 
137], is a kind of cell surface antigen that is characteristic when myeloid precursors 
differentiate into mature monocytic cells. Then, differentiated cells after treatment 
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with As2S2 were detected by CD11b expression as well as by cell-size characterization 
at 48 h, followed by examining NBT reduction ability at 72 h. The cells treated with 
As2S2 at concentrations of 0.5, 2, and 8 μM for 48h increase the CD11b-positive cells 
tenuously in the presence of 0.5 and 2 μM, and significantly to 56% in the presence of 
8 μM As2S2 (Fig. 3-2A) (p<0.05). When the cells were treated with As2S2 at a 
concentration of 8 μM for 24-72 h, the degree of cell differentiation peaked by 17 
times of control at 48 h (Fig. 3-2B) (p<0.05). The NBT-positive cells significantly 
increased to approximately 3 times of control after incubation with As2S2 at 
concentrations of 0.5, 2, and 8 μM for 72 h (Fig. 3-2C) (p<0.05). Sizes of the cells 
changed to be larger than the untreated cells, which could be observed by FSC on the 
X-axis (Fig. 3-2D). Histograms showed the changes of CD11b expression of cells 
following treatment of As2S2 at concentrations of 0.5, 2, and 8 μM for 48 h (Figs. 
3-2Ea-c), and at a concentration of 8 μM for 24 to 72 h (Fig. 3-2F).  
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Fig. 3-2. As2S2-induced differentiation in HL-60 cells. CD11b-positive cells treated with As2S2 
at concentrations of 0.5, 2, and 8 μM for 48 h (A) or cells treated with 8 μM As2S2 for 24 to 72 h 
(B). NBT reduction positivity in HL-60 cells following treatment with As2S2 at concentrations of 
0.5, 2, and 8 μM for 72 h (C). Data are the mean ± SD of 3 independent experiments. *p<0.05 as 
compared with control group. (D) HL-60 cells treated with 0.5, 2, or 8 μM As2S2 were analyzed 
with flow cytometry, and the data were presented by histograms plotted by FSC (abscissa), which 
reflects cell size. Histograms showed the changes of CD11b expression in HL-60 cells, as assessed 
by MFI, following treatment with As2S2 at concentrations of 0.5 (a), 2 (b), and 8 (c) μM, 
respectively, for 48 h (E), and those in cells following treatment with 8 μM As2S2 for 24 to 72 h 
(F). Shaded or unshaded area in D-F represents the data of untreated- or treated- cells, respectively. 
Data are the MFI. 
 
3.3.2 Apoptosis and viability of cells treated with As2S2 
As2S2 did not induce apoptosis and inhibition of viability at concentrations of 0.5, 
2, and 8 μM for 48 h or at a concentration of 8 μM for 24 to 72 h. In contrast, As2S2 
decreased apoptosis and increased cell viability at concentrations of 2 and 8 μM for 
48 h or at a concentration of 8 μM for 48 to 72 h compared with control, when 
apoptosis was identified by Annexin V-staining (Fig. 3-3A, B) and viability 
determined by a PI exclusion (Fig. 3-3C, D), respectively. Dot plot analysis of 
PI/Annexin-V stained cells showed the changes of dead cells (FL1) and apoptotic 
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cells (FL2) following treatment of As2S2 at concentrations of 0.5, 2, and 8 μM for 48 
h, respectively (Fig. 3-3E).  
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Fig. 3-3 Apoptosis and viability in As2S2-treated HL-60 cells. The percentages of apoptotic 
cells treated with 0.5, 2, and 8 μM As2S2 for 48 h (A), and those treated with 8 μM As2S2 for 24 to 
72 h (B). The percentages of viability of cells treated with 0.5, 2, and 8 μM As2S2 for 48 h (C), and 
those treated with 8 μM As2S2 for 24 to 72 h (D). Data are the mean ± SD of 3 independent 
experiments. *p<0.05 as compared with control group. (E) Dot plot analysis showing dead cells 
stained by PI (FL1) and apoptotic cells stained by Annexin V (FL2) following treatment with 
As2S2 at concentrations of 0.5 (a), 2 (b), and 8 (c) μM, respectively, for 48 h. 
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3.3.3 Involvement of oxidative stress in the As2S2-induced cell differentiation 
Cells incubation for 0.5 to 24 h in the presence of 0.5, 2, and 8 μM As2S2 
generated the cellular ROS, and the levels of ROS peaked at 1 h notably at 8 μM (Fig. 
3-4A). After incubation for 1 h, the cellular ROS rapidly increased to 109%, 123%, 
and 129% of control at the concentrations of 0.5, 2, and 8 μM, respectively (Fig. 
3-4B). The changes of cellular ROS were shown in histograms with the agent 
concentrations of 0.5, 2, and 8 μM for 0.5 to 24 h (Fig. 3-4C).  
                                    
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3-4. Induction of cellular ROS by treatment with As2S2 at concentrations of 0.5, 2, and 8 
μM in HL-60 cells. (A) Changes in levels of ROS in cells incubated with As2S2 for 0.5 to 24 h.  
ROS levels were presented as the relative MFI, which were defined as: (sample MFI/control MFI) 
×100. (B) The levels of ROS in cells incubated with As2S2 for 1 h. The data are the MFI of DCF.  
Data are the mean ± SD of 3 independent experiments. * p<0.05 as compared with control group. 
(C) Histograms showing the changes of cellular ROS, as assessed by MFI, following treatment of 
cells with As2S2 at concentrations of 0.5 (a), 2 (b), and 8 (c) μM, respectively, for 0.5 to 24 h.  
Shaded or unshaded area represents the data of untreated- or treated- cells, respectively. Data are 
the MFI. 
A B 
MFI for ROS 
C 
39 
 
The effects of H2O2 on As2S2-induced cell differentiation were assessed by 
CD11b-positive cells in the presence of As2S2 and H2O2 alone or in combination. 
H2O2 alone at a concentration of 20 μM showed a significant effect to increase 
CD11b-positive cells as compared to control (Fig. 3-5A) (p<0.05). When cells were 
pre-incubated with 20 μM H2O2 for 1 h followed by incubation with As2S2 for 48 h, as 
compared to treatment with As2S2 alone, the number of CD11b-positive cells 
significantly increased in the presence of H2O2 and As2S2 in combination at 
concentrations of 20 and 0.5 or 2 μM, respectively (Fig. 3-5A). As2S2 at 0.5 and 2 μM 
generated a relative low level of cellular ROS (Fig. 3-4A).  Treatment of cells with 8 
μM As2S2 produced the highest concentration of ROS (Fig. 3-4A), as well as the 
highest percentage of CD11b-positive cells (Fig. 3-5A). Whereas, the combined 
treatment with H2O2 and 8 μM As2S2 decreased, rather than increased, the percentages 
of CD11b-positive cells, as compared to the treatment of cells with 8 μM As2S2 alone 
(Fig. 3-5A) (p<0.05). The changes of CD11b expression in cells treated with H2O2 
and As2S2 in combination at As2S2 concentrations of 0.5, 2, and 8 μM for 48 h were 
shown in Fig. 3-5B as histograms. 
 
                                              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3-5 The modifying effects of hydrogen peroxide (H2O2) on As2S2-induced differentiation 
in HL-60 cells.  Cells were incubated with 20 μM H2O2 and As2S2 alone at concentrations of 0.5 
(A0.5), 2 (A2), and 8 (A8) μM, respectively, or pre-incubated with 20 μM H2O2 for 1 h before 
treatment with As2S2 for 48 h (H2O2 + A). After treatment, the cells were stained for CD11b and 
then analyzed with flow cytometer. Data are the mean ± SD of 3 independent experiments.  
Means were compared by 1-way ANOVA. *p<0.05 as compared with control group. (B) 
Histograms showing the changes of CD11b expression in HL-60 cells, as assessed by MFI, treated 
with 20 μM H2O2 and As2S2 alone or in combination with As2S2 at concentrations of 0.5, 2, and 8 
μM, respectively, for 48 h. a, Shaded or unshaded (open line) area are the data of untreated- or 
treated- cells with 20 μM H2O2. b-d, Open line represent the MFI in cells treated with H2O2 alone. 
Thin or thick solid line represent the MFI in cells treated with As2S2 at concentrations of 0.5 (b), 2 
(c) and 8 (d) μM alone or combination with H2O2, respectively. 
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3.3.4 Cellular GSH level 
Cells were treated with As2S2 at concentrations of 0.5, 2, and 8 μM for 0.5 to 24 h, 
and levels of cellular GSH were measured. Cellular GSH concentration increased to 
110% of control at 0.5 h, and then the level rapidly declined and dropped to the 
minimum at 6 h (Fig. 3-6A). At this time, cells treated with 8 μM As2S2 showed a 
significant GSH depletion to 86% of control (Fig. 3-6B). As showed in Fig. 3-4A, 
after treatment of As2S2 for 0.5 to 24 h, cellular ROS level tenuously increased at 0.5 
h, and then rose to the maximum at 1 h. The changes of cellular GSH level were 
shown in Fig. 3-6C as histograms.   
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Fig. 3-6. Changes of cellular GSH 
by treatment with As2S2 at 
concentrations of 0.5, 2, and 8 μM 
in HL-60 cells. (A) Changes in levels 
of GSH in cells incubated with As2S2 
for 0.5 to 24 h. GSH levels are 
presented as the relative MFI, which 
were defined as: (sample MFI/control 
MFI) × 100. (B) The levels of GSH in 
cells incubated with As2S2 for 6 h.  
The data are the MFI related from 
ortho-phthaldialdehyde-GSH. Data are 
the mean ± SD of 3 independent 
experiments. *p<0.05 as compared 
with control group. (C) Typical 
histograms showing the changes of 
cellular GSH, as assessed by MFI, 
following treatment with As2S2 at 
concentrations of 0.5 (a), 2 (b), and 8 
(c) μM for 0.5 and 6 h, respectively. 
Shaded or unshaded area represents 
the data of untreated- or the treated- 
cells, respectively.   
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3.3.5 Activation of p38 MAPK 
After treatment of cells with As2S2 at a concentration of 8 μM for 1 to 48 h, as 
compared to control, the level of p38 MAPK initially decreased to 82% at 1 h, and 
then gradually increased to 115% at 48 h (Fig. 3-7A). Conversely, the levels of 
cellular ROS initially increased to 130% at 1 h, and then gradually decreased to 75% 
at 48 h (Fig. 3-7B). The changes of p38 MAPK activation after treatment with As2S2 
were also shown as histograms in Fig. 3-7C.  
After treatment with 8 μM of As2S2 for 1, 6, 24 and 48 h, phosphorylation of p38 
MAPK was investigated using western blot. As shown in Fig. 3-7D, endogenous p38 
MAPK activation was constantly observed in untreated HL-60 cells (control groups) 
during the incubation period based on the detection of the similar expression level of 
phospho-p38 MAPK. Furthermore, compared to control groups, the expression level 
of phospho-p38 MAPK in the As2S2 treated cells appeared to increase at 24 h. 
However, in contrast to FACS data showing approximate 15% increase in the 
expression level of phospho-p38 MAPK at 48 h, its expression level seemed to 
decrease at this time point. It should be noted that there were no changes in the 
expression levels of total p38 MAPK expression observed in both untreated and 
treated cells. 
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Fig. 3-7. Changes in p38 MAPK activity in HL-60 cells treated with As2S2. (A) p38 MAPK 
activation was detected by PE-labeled phosphorylated p38 MAPK antibody. Cells were treated 
with 8 μM As2S2 for 1 to 48 h. Data are the mean ± SD of 3 independent experiments. *p<0.05 as 
compared with control group. (B) Changes in levels of cellular p38 MAPK compared with ROS in 
cells treated with 8 μM As2S2 for 0.5 to 24 h. p38 MAPK and changes of ROS levels are presented 
as the relative MFI, both of which were defined as: (sample MFI/control MFI) × 100.  (C) 
Typical histograms showing the changes of activation of p38 MAPK, as assessed by MFI, 
following treatment with As2S2 at a concentration of 8 μM for 1 to 48 h. Shaded or unshaded area 
represents the data of untreated- or the treated- cells, respectively. Data are the MFI. (D) Detection 
of phosphorylated p38 MAPK in As2S2-treated HL-60 cells. After treatment with 8 μM of As2S2 
for 1, 6, 24 and 48 h, the expression profiles of phospho-p38 MAPK (active form of p38, P-p38), 
total p38 MAPK (p38) and β-actin proteins in HL-60 cells were analyzed as described in Materials 
and Methods. 
 
3.3.6 Depletion of MMP 
The relative value of MMP significantly declined to 65% of control in cells 
treated with 8 μM As2S2 for 48 h (p<0.05), whereas no notable changes were observed 
in cells treated with As2S2 at concentrations of 0.5 and 2 μM (Fig. 3-8A). Under 
treatment with 8 μM As2S2 for 24 to 72 h, cells showed a minor change in MMP at 24 
h, and significant depletions of MMP were observed at 48 h and 72 h (Fig. 3-8B) 
(p<0.05). Noticeably, the minimum of MMP level was at 48 h, and at this time, the 
level of CD11b positive cells increased to the maximum (Fig. 3-8C). The depletions 
of MMP were also shown as histograms in Fig. 3-8D.  
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Fig. 3-8. Depletion of MMP related to As2S2-induced differentiation in HL-60 cells. (A) 
Changes in levels of MMP in cells incubated with As2S2 at concentrations of 0.5, 2 and 8 μM for 
48 h. (B) Depletion of MMP in cells incubated with As2S2 at a concentration of 8 μM for 24 to 72 
h. Data are the mean ± SD of 3 independent experiments. *p<0.05 as compared with control group. 
(C) Changes in levels of CD11b expression compared with MMP and p38 MAPK in cells 
incubated with 8 μM As2S2 for 24 to 72 h. CD11b expression, MMP and p38 MAPK levels are 
presented as the relative MFI, each of which was defined as: (sample MFI/control MFI) × 100. 
(D) Typical histograms showing the changes of MMP, as assessed by MFI, following treatment 
with As2S2 at a concentration of 8 μM for 24 to 72 h in HL-60 cells. Shaded or unshaded area 
represents the data of untreated- or treated- cells, respectively. 
 
3.3.7 Effects of inhibition of p38 MAPK activation on As2S2-induced 
differentiation 
As showed in Fig. 3-2B and Fig. 3-8C, when the cells were treated with As2S2 at 
a concentration of 8 μM for 24-72 h, the CD11b-positive cells increased to the 
maximum at 48 h, while that significantly decreased at 72 h, and at this time, the 
activation of p38 MAPK rose to the maximum. Then, the effects of activation of p38 
MAPK on As2S2-induced differentiation were assessed. After treatment of cells with 8 
μM As2S2 alone or combination with 10 μM SB203580, an inhibitor of p38 MAPK, 
for 72 h, the CD11b-positive cells significantly increased following treatment with 
combination as compared to that with As2S2 alone (Fig. 3-9A) (p<0.05). The changes 
of CD11b-positive cells treated with 8 μM As2S2 alone or combination with 10 μM 
SB203580 were also shown as histograms in Fig. 3- 9B. 
                                        
         
            
 
 
 
 
 
Fig. 3-9. The modified effects of inhibitor (SB203580) 
of p38 MAPK on As2S2-induced differentiation in 
HL-60 cells. Cells were incubated with 10 μM 
SB203580 (SB) and 8 μM As2S2 (A8) alone or in 
combination (SB + A8) for 72 h, respectively.  After 
treatment, the cells were stained for CD11b and then 
analyzed with flow cytometer. Data are the mean ± SD 
of 3 independent experiments. Means were compared by 
1-way ANOVA. *p< 0.05 as compared with 8 μM As2S2 
(A8) alone. (B) Typical histograms showing the changes 
of CD11b-positive cells treated with 10 μM SB203580 
(a), 8 μM As2S2 (b), and combination of 10 μM 
SB203580 with 8 μM As2S2 (c), respectively, for 72 h.   
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3.4 DISCUSSION 
In this Chapter, I showed that 16 μM of As2S2 induced remarkable proliferation 
inhibition in HL-60 cells, while 0.5, 2, and 8 μM of As2S2 did not produce inhibition 
of proliferation (Fig. 3-1). Contrarily, 2 and 8 μM As2S2 enhanced the viability and 
attenuated apoptosis in HL-60 cells following treatment for 48 h (Fig. 3-3A, B, C, and 
D). Similarly, a previous report has demonstrated that 8 μM As4S4 did not induce 
apoptosis in HL-60 cells following treatment for 48 h [123]. It is noteworthy that 
treatment with 5 μM As2S2 for 48 h induced apoptosis in K562, a human chronic 
myelogenous leukemia cell line [73]. Thus, the difference in differential response 
could be attributed to different cell types.  
HL-60 is a leukemia cell line blocked at the level of promyelocytic 
differentiation. On the other hand, the cells can be induced to differentiate into 
neutrophils and other functional cells depending on the inducer molecules. The 
differentiation is accompanied by the increase in CD11b expression level and the 
acquisition of a number of functions such as NBT-reducing activity [21, 87]. It has 
been reported that arsenic compounds such as As2O3 and As4S4 induce differentiation 
in HL-60 cells, as evidenced by the increased CD11b expression level and acquisition 
of NBT reduction ability [123, 124, 141,]. Similarly, our experimental data 
demonstrated that the CD11b-positive cells significantly increased by 17 times at 48 h 
(Figs. 3-2A, B) and the NBT-positive cells increased at 72 h by 3 times (Fig. 3-2C), 
after treatment of cells with 8 μM As2S2, as compared to control. The differentiated 
cells also showed an increase in size (Fig. 3-2D). Whereas, the number of CD11b 
positive cells at 48 h culture with 8 μM As2S2 was reduced after 72 h. The underlying 
reason for the reduction after 72 h (Fig. 3-2B) can be explained by a negative 
regulatory feedback as a result of an activation of p38 MAPK signaling cascade. p38 
MAPK is well known as a sensor of moderate oxidative stress, and p38 MAPK 
activation paralleled with the intracellular ROS accumulation (Fig. 3-7B).  We 
observed that a decrease in CD11b expression level was accompanied by the p38 
MAPK activation (Fig. 3-8C), suggesting that p38 MAPK activation resulted from 
oxidative stress is implicated in the negative regulation of cell differentiation.  
Furthermore, our experimental data showed that p38 MAPK inhibitor restored the 
CD11b expression level (Fig. 3-9), providing support for our proposal. Indeed, Giafis 
et al. has demonstrated that inhibition of p38 MAPK enhances As2O3 induced 
differentiation in NB4 cells [29]. 
Compared with experimental results from flow cytometry analysis, an increase in 
the expression level of phosphorylated p38 was observed after treatment with 8 μM 
As2S2 for 24 h, rather than 48 h. Conversely, the expression level of phosphorylated 
p38 seemed to decrease at 48 h. The discrepancy in the expression level of 
phosphorylated p38 between western blot and flow cytometry data might be attributed 
to different analysis techniques. Compared with western blot analysis, flow cytometry 
is considered to allow for screening single cell to offer the more precise expression 
level of phosphorylated p38. More importantly, western blot analysis also indicated 
the increase in the expression level of phosphorylated p38 in As2S2-treated HL-60 
cells. Furthermore, we demonstrated that SB203580, p38 MAPK inhibitor, 
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significantly enhanced the CD11b expression induced by As2S2 treatment (Fig. 3-9). 
Taken together, these findings suggest that p38 MAPK is implicated in 
As2S2-mediated cellular responses including differentiation.  
ROS play very critical roles in the determination of cell fate by eliciting a wide 
variety of cellular responses, such as proliferation, differentiation and apoptosis. 
Moderate levels of ROS promote cell survival and proliferation; however, once ROS 
exceed the capacity of the antioxidant system including GSH to remove them, the 
cells suffer so-called “oxidative stress”, and are leading to severe dysfunctions or 
deaths [146]. We have demonstrated a transient increase in ROS levels in HL-60 cells 
treated with As2S2. A transient increase in the amount of intracellular GSH was 
observed 0.5 h after treatment with As2S2, followed by a substantial decrease in the 
GSH content after that. These results suggest that As2S2 induced oxidative stress in 
HL-60 cells through the depletion of GSH, although a transient increase in GSH 
content was observed as a result of response to increased ROS production.  
Furthermore, as we indicated in this study, treatment with As2S2 ranging from 0.5 
to 8μM for 24 to 48 h dramatically augmented the percentage of the CD11b-positive 
cells (Figs. 3-2A, B). Importantly, pretreatment with H2O2 significantly increased the 
percentage of the CD11b-positive cells induced by relatively lower concentrations of 
As2S2 (0.5 or 2 μM) when compared to each alone (Fig. 3-5A). On the other hand, 
compared to the treatment with 8 μM As2S2 alone, combination of 8 μM As2S2 and 
H2O2 significantly decreased the percentage of the CD11b-positive cells (Fig. 3-5A). 
Taken together, these results suggested that oxidative stress induced by As2S2 
positively contribute to HL-60 cell differentiation, and that 8 μM As2S2 would be the 
more adequate concentration to achieve a high level of differentiation.    
The association of oxidative stress with cell differentiation via the activation of 
MAPK signaling has been documented [121]. Both extent and duration of activation 
of MAPKs contribute to the determination of cell fate, such as survival, differentiation 
and apoptosis [86]. p38 MAPK is considered as a sensor of moderate oxidative stress, 
and this kinase was activated in a ROS-dependent manner [104]. Interestingly, p38 
MAPK has previously been shown to mediate both proapoptotic/growth inhibitory 
[55] and antiapoptotic/progrowth [61] signals in different systems, apparently 
depending on the stimulus and cell type involved. A recent paper has demonstrated 
that inhibition of p38 MAPK enhances differentiation induced by As2O3 in NB4 cells, 
suggesting that p38 MAPK signaling cascade is activated in a negative regulatory 
feedback manner to control induction of mediated antileukemic effects [29]. Our 
study demonstrated that an activation of p38 MAPK was observed followed by the 
accumulation of intracellular ROS. Interestingly, the decrease in expression level of 
phospho-p38 MAPK at 1 h after treatment with As2S2 was also observed compared to 
0-h point. This discrepancy may be explained that the stress resulted from medium 
change could contribute to relatively higher expression level at 0-h point. It is 
noteworthy that a decrease in CD11b expression level was accompanied by the 
activation of p38 MAPK (Fig. 3-8C), although the number of differentiated cells 
increased to the maximal level at 48 h post-treatment with As2S2 (Fig. 3-2B). 
Furthermore, an inhibitor (SB203580) of p38 MAPK restored the CD11b expression 
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level (Fig. 3-9). Taking these previous results and our observations into account, we 
suggested that activation of p38 MAPK resulted from oxidative stress seems to be 
implicated in the negative regulation of the differentiation.   
We also surprisingly observed that 8 μM As2S2 did not induce apoptosis and 
decrease cell viability, and instead, attenuated apoptosis and enhanced cell viability, as 
compared to control (Figs. 3-3B, D). At the same time, a significant restoration of 
decreased MMP was observed at 72h post-treatment with 8 μM As2S2, although the 
decrease in MMP was confirmed at 48 h point. It is well known that the mitochondria 
can be viewed as a central regulator of the decision between cellular survival and 
death [8]. The Bcl-2 family proteins play important roles in the regulation of 
apoptosis by targeting to the mitochondria to exert their proapoptotic or antiapoptotic 
effects. There is evidence that the antiapoptotic function of Bcl-2 is dependent on its 
phosphorylation status rather than its expression level [63, 7]. Of note, a recent study 
demonstrated that p38 MAPKs are upstream regulators for the phosphorylation of 
Bcl-2 [63]. Furthermore, a previous report demonstrated that inhibition of p38 MAPK 
enhanced arsenic-induced Bcl-2 down-regulation, which suggested that p38 MAPK 
up-regulates Bcl-2 expression and generation of antiapoptotic responses [29]. Taken 
together, apoptosis suppression could be attributed to MMP restoration associated 
with Bcl-2 upregulation as a result of negative feedback control of p38 MAPK 
activation. 
 
3.5 CONCLUSION  
The following observations (1)-(4) obtained in this Chapter suggest that the 
activation of p38 MAPK resulted from oxidative stress implicated in the negative 
regulation of As2S2 induced differentiation in HL-60 cells. 
(1) As2S2 induced cell differentiation based on the increment in CD11b 
expression, NBT-positive cells, and cell size.   
(2) A transient increase in ROS level along with intracellular GSH level was 
observed after As2S2 treatment.   
(3) p38 MAPK activation gradually increased after ROS generation and 
sustained during the As2S2 induced cell differentiation.  
(4) Decreased CD11b expression was accompanied by p38 MAPK activation, 
and p38 MAPK inhibitor restored the CD11b expression.    
 
 
 
 
 
 
 
 
 
 
 
47 
 
Chaper 4 
Arsenic disulfide induced apoptosis and concurrently promoted erythroid 
differentiation in cytokine-dependent MDS-progressed leukemia cell line F-36p 
with complex karyotype including monosomy 7 
 
4.1 INTRODUCTION 
MDS are a group of clonal disorders of haematopoietic stem cells characterised 
by ineffective haematopoiesis and a tendency to evolve into AML [50]. Chromosomal 
abnormalities are found in 40-60% of MDS patients, and karyotypes with monosomy 
7 (-7) and complex abnormality were defined as the unfavorable cytogenetics for 
MDS progression to AML (MDS/AML [32]. It was reported that more than 60% of 
MDS/AML patients have abnormal karyotypes, including complex type abnormalities 
at the onset of AML [111]. MDS/AML patients with complex type abnormalities 
including -7 is considered to be an unfavorable risk subgroup [34, 68]. These results 
were also confirmed by our clinical investigations [51-53]. 
In our recent clinical trials, we have revealed that QHP is effective in the 
treatment of MDS, especially in patients with the erythroid improvement is significant, 
without serious adverse drug reaction observed even on long time [133-135]. 
Furthermore, a high responding rate (80.8%) was also observed, with blast cells 
decrease and hematologic improvement, in patients with moderate- and high-risk by 
increasing the daily dose of QHP [74]. It is a spring of our new observation that QHP 
was notably effective in treating two patients with acute erythroid leukemiaprogressed 
from MDS, although these two patients presented with the unfavorable cytogenetics 
of -7 and complex karyotype, respectively [35]. These results indicated that QHP is 
effective in treating MDS or MDS/AML even with the poor karyotype, and its 
therapeutic efficacy could be enhanced by increasing the Xiong huang content in the 
formula, which could be attributed to As2S2, the most important component of Xiong 
huang.  
F-36p cell line was established from a patient diagnosed with refractory anemia 
with excess blasts, approximately 5 months after the initial diagnosis, and the disease 
progressed to overt leukemia [15]. This cell line requires granulocyte macrophage 
colony-stimulating factoror interleukin- 3 for continuous growth, and the cells die 
within several days when these cytokines are depleted. The majority of the established 
cells had a homogeneous karyotype: 43,Y, Xp+, -5, -7, -13, -16, -17, -19, -21,2q-, 9p+, 
10q+, +4mar. This cell line has a multilineage phenotype, suggesting that the 
transformation event occurred in a multipotent stem cell. It is also evident that the 
F-36p cells can be induced to differentiate into the erythroid lineage in the presence of 
erythropoietin. Thus, F-36p is a desirable cell line for study on the effective 
mechanisms of As2S2 in the treatment of MDS or MDS/AML. 
 
4.2 MATERIALS AND METHODS 
 
4.2.1 Reagents 
The reagents used in this Chapter are same as those described in Chapters 1-3.  
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4.2.2 Cells and cell culture  
F-36P cellsestablished from a patient with MDS, were obtained from RIKEN 
Cell Bank (Tsukuba, Japan). F-36p cells were cultured in RPMI-1640 
supplemented with 5% inactivated FBS and 5 ng/mL recombinant human 
interleukin- 3 ( Kirin, Japan) at 37° C in a 5% CO2 humidified atmosphere. 
 
4.2.3 MTT assay 
The assay was carried out according to the procedures as described in Chapter 3. 
 
4.2.4 Apoptosis and viability assays  
The assay was carried out according to the procedures as described in Chapter 3. 
 
4.2.5 Assessment of erythroid differentiation  
F-36p cells (1 × 106/mL) were treated with the indicated concentrations of As2S2. 
After incubation for 72 h, cells were washed twice by PBS containing 2% FBS and 
then resuspended with 100 μl PBS containing 2% FBS. Subsequently, 10 μl 
FITC-conjugated CD235a (Glycophorin) antibody was added, and cells were 
incubated in the dark at 4 ° C for 30 min. After the incubation, cells were resuspended 
in 400 μl PBS containing 1% FNB, and the cells were analyzed by Becton Dickinson 
flow cytometry. Isotypic mouse IgG1 was used to set threshold parameters. A total of 
30,000 non-gated cells were analyzed. 
 
4.2.6 Statistics 
Data were shown as the mean ± standard deviation (SD) of three independent 
experiments. Differences were estimated by one-way ANOVA. A value of p<0.05 was 
considered significant. 
 
4.3 RESULTS 
 
4.3.1 Cell proliferation inhibited by As2S2   
F-36p cells were continuously treated with As2S2 at a concentration range of 0.25 
to 32.0 μM for 72 h, and cell growth was measured in an MTT assay. The IC50 value 
of As2S2 on the F-36p cell growth was 6 μM. As2S2 produced inhibition of 
proliferation in F-36p cells in a dose-dependent manner (Fig. 4-1). 
 
Fig. 4-1. Effects of As2S2 on 
proliferation of F-36p cells. 
Cells were treated with serial 
concentrations of As2S2 for 72 h.  
Cell proliferation was determined 
by an MTT assay. Data are the 
mean ± SD of 3 independent 
experiments. 
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4.3.2 Apoptotic cells induced by As2S2 
Apoptotic cells were identified by annexin V-staining. After treatment with 
As2S2 at concentrations of 2, 8 and 16 μM for 72 h, the apoptotic cells significantly 
increased as compared to control (p<0.05), which were in a dose-dependent manner as 
analyzed by the multiple comparisons (p<0.05) (Fig. 4-2A). Histograms also showed 
the changes of apoptotic cells following treatment with As2S2 at concentrations of 2, 8 
and 16 μM for 72 h (Fig. 4-2B).  
A                                       B 
 
 
 
 
 
 
 
 
Fig. 4-2. Comparison of levels of apoptotic cells (A) and the 
typical histograms of the data (B). Cells were treated with 
As2S2 at concentrations of 0 (a), 2 (b), 8 (c) and 16 (d) μM for 
72 h. In A, the data are the mean ± SD of 3 independent 
experiments. * p<0.05 as compared with control group, and in 
dose-dependent by the multiple comparisons. 
 
4.3.3 Cell viability after treatment with As2S2 
Cell viability was determined by a PI exclusion. After treatment with As2S2 at 
concentrations of 2, 8 and 16 μM for 72 h, the cell viability significantly decreased as 
compared to control (p<0.05), which were in a dose-dependent manner as analyzed by 
the multiple comparisons (p<0.05) (Fig. 4-3A). Dot plot analysis also showed the 
changes of inviable cells (Fig. 4-3B) following treatment of As2S2 at concentrations of 
2, 8 and 16 μM for 72 h. 
 
A                               B 
           
 
 
 
 
 
 
 
 
 
 
Fig. 4-3. Comparison of viability of cells assessed by a PI exclusion (A) and the typical 
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intensity dots of the data of inviable cells (B). Cells were treated with As2S2 at concentrations 
of 0 (a), 2 (b), 8 (c) and 16 (d) μM for 72 h. In A, the data are the mean ± SD of 3 independent 
experiments. *p<0.05 as compared with control group, and in dose-dependent by the multiple 
comparisons.   
 
4.3.4 Erythroid differentiation of cells induced by As2S2 
Erythroid differentiated cells were detected by CD235a (GpA) expression. After 
treatment of cells with As2S2 at concentrations of 2, 8 and 16 μM for 72 h, the 
CD235a-positive cells significantly increased as compared to control (p<0.05), which 
were in a dose-dependent manner as analyzed by the multiple comparisons (p<0.05) 
(Fig. 4-4A). Histograms showed the changes of CD235a expression of cells following 
treatment with As2S2 at concentrations of 2, 8 and 16 μM for 72 h (Fig. 4-4B). 
 
A                                      B 
 
 
 
 
 
 
 
 
 
 
Fig. 4-4 Comparison of levels of CD235a-positive cells (A) 
and the typical histograms of the data (B).  Cells were 
treated with As2S2 at concentrations of 0 (a), 2 (b), 8 (c) and 
16 (d) μM for 72 h. In A, the data are the mean ± SD of 3 
independent experiments. *p<0.05 as compared with control 
group, and in dose-dependent by the multiple comparisons. 
 
4.4 DISCUSSION  
MDS/AML patients have higher probabilities of multidrug resistance to 
chemotherapy, lower rates of complete remission, and the poor prognosis [71]. 
Univariate analyses showed that the hemoglobin level and cytogenetic abnormalities 
were factors that contributed to the overall survival [68]. The data have shown that 
MDS/AML patients tended to have complex type abnormalities including -7, which is 
considered to be an unfavorable risk subgroup [34, 68]. The response rate to 
aggressive chemotherapies such as AML induction regimens for these patients was 
41-72% and median survival time was 9-14.5 months [41]. In a recent report of the 29 
patients with MDS/AML, 21 patients had an abnormal karyotype. Among them, 13 
had complex type abnormalities and/or -7, and the response rate in the patients with a 
normal karyotype was significantly better than in those with an abnormal karyotype 
(62.5% vs. 4.8%) [68]. 
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In addition, patients with MDS or MDS/AML often have symptoms due to low 
haemoglobin levels [99]. Much of the effort has been devoted to the correction of 
anemia. Transfusion support is still the mainstay of the treatment of anemia, and 
which was the sole therapeutic option in many cases [2]. Recombinant human 
erythropoietin offer substantial possibilities of haematological improvement, while 
response was poor in these patients [113,117]. Hematopoietic stem cell 
transplantation is thought to be the only promising treatment for fundamental solution 
of the disease. However, it is generally restricted to younger adults who have an 
HLA-matched donor. 
Our clinical trials have documented that QHP is effective in the treatment of 
MDS or MDS/AML patients by hematologic improvement and blast cells decrease, 
without serious adverse drug reaction observed even on long time [35, 74, 133, 134, 
135]. Especially, the life spans of two MDS/AML patients were 8 and 2 years, 
respectively, which are longer than those of the other reports [34, 68], after treatment 
with QHP by increasing the Xiong huang content in the formula, although these 
patients presented with the unfavorable cytogenetics of -7 and complex karyotype, 
respectively [35]. Xiong huang contains > 90% As2S2 based on the quality standard in 
Chinese Pharmacopeia in 2010 edition. The therapeutic efficacy of QHP could be 
enhanced by increasing the Xiong huang content in the formula, which could be 
attributed to As2S2. 
F-36p cell line was established from a patient with AML progressed from MDS 
[68]. Chromosomal study of the freshly obtained bone marrow cells indicated the 
presence of normal and abnormal clones. Thirteen of 18 mitotic figures showed 
normal karyotype (43, XY). Four showed essentially the same karyotype: -5, -7, -9, 
-17, -18, 19p+, and some markers, and additional random loss was also observed in 
each mitotic figure. The majority of the established cells had a homogeneous 
karyotype: 43,Y, Xp+, -5, -7, -13, -16, -17, -19, -21,2q-, 9p+, 10q+, +4mar. This cell 
line has a multilineage phenotype and can be induced to differentiate into the 
erythroid lineage in the presence of erythropoietin.  F-36p cell line might provide a 
desirable cell model for the study of effective mechanisms of As2S2 in the treatment of 
MDS or MDS/AML. In the present study, As2S2 could inhibit proliferation and 
viability, induce apoptosis, and concurrently promote erythroid differentiation in 
F-36p cells, which were in a dose-dependent manner.  
In the previous Chapters, the mechanisms of As2O3-induced apoptosis were well 
documented in leukemia cells, which were via depletion of intracellular glutathione, 
disruption of mitochondrial membrane potential and activation of caspase-3 [44, 48]. 
While there is little information of arsenic-induced apoptosis or the involvement of 
apoptosis in F-36p cells, the expression of P2 purinergic receptor genes was reported 
to be observed in these cells, and extracellular ATP could induce apoptosis and control 
cell cycle via P2 receptor genes [139]. F-36p cells can be induced to differentiate into 
the erythroid lineage in the presence of erythropoietin [68]. It was reported that 
STAT5, signal transducers and activators of transcription, appears to mediate 
transcriptional regulation of cyclin D1, thereby contributing to cytokine-dependent 
growth of F-36p cells [85]. The in vitro kinase assay demonstrated that the 
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erythropoietin-initiated signal transduction of erythroid differentiation can be 
occurred through Src, a prototype molecule of Src family PTKs, and 
phosphatidylinositol 3-kinase (PI3-kinase) in F-36p cells [95, 69]. The association of 
As2S2 inducing apoptosis and erythroid differentiation promotion with these 
molecules is needed to assess in future studies. 
 
4.5 CONCLUSION 
It can be concluded from the following observations (1)-(4) that As2S2 could 
inhibit proliferation and viability, induce apoptosis, and concurrently promote 
erythroid differentiation dose- dependently in F-36p cells. This, to our knowledge, is 
the first discription that As2S2 can inhibit proliferation and viability, induce apoptosis, 
and concurrently promote erythroid differentiation in cytokine-dependent 
MDS-progressed human leukemia cell line F-36p with complex karyotype including 
-7.   
(1) As2S2 inhibited the proliferation of F-36p cells.   
(2) The apoptotic cells significantly increased by As2S2 in a dose-dependent 
manner.  
(3) The cell viability was significantly inhibited by As2S2 dose-dependently.  
(4) Significant increase in CD235a-positive cells was concurrently observed by 
As2S2 dose-dependently. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
53 
 
GENERAL DISCUSSION AND CONCLUSIONS 
  
MDR is recognized as one of the most common causes of failure of 
chemotherapy in the treatment of cancer patients [45-47]. P-gp is an ATP-binding 
cassettetransporter, which hydrolyses ATP and expels cytotoxic drugs from 
mammalian cells [102]. The data in Chapter 1 revealed that 94% of MOLT-4/DNR 
cells express P-gp. MOLT-4/ DNR cells exhibited significantly higher P-gp efflux 
activity than parental MOLT-4 cells. However, both parental MOLT-4 and resistant 
MOLT-4/DNR cell lines were highly sensitive to As2O3. As2O3 similarly inhibited 
growth and induced apoptosis in these two cell lines, and the effects of As2O3 were 
time- and dose-dependent, which suggested that P-gp in MOLT-4/DNR cells was not 
involved in the detoxification of As2O3. Furthermore, the data in Chapter 2 showed 
that As2O3 induces apoptosis in MOLT-4 and MOLT-4/DNR cells via the depletion of 
intracellular GSH, and subsequent MMP disruption and caspase-3 activation. 
As2S2, the most important component of Xiong huang which contains > 90% 
As2S2 based on the quality standard in Chinese Pharmacopeia in 2010 edition, was a 
candidate for its good therapeutic reputation and perceived low toxicity in traditional 
medicines. The data in Chapter 3 demonstrated that As2S2 induced cell differentiation 
in HL-60 cells based on the increment in CD11b expression, NBT-positive cells, and 
cell size. A transient increase in ROS level along with intracellular GSH level was 
also observed. p38 MAPK activation gradually increased after ROS generation and 
sustained during the cell differentiation. Decreased CD11b expression was 
accompanied by p38 MAPK activation, and p38 MAPK inhibitor restored the CD11b 
expression. These results suggest that the activation of p38 MAPK resulted from 
oxidative stress seems to be implicated in the negative regulation of As2S2 induced 
differentiation in HL-60 cells.   
F-36p cell line was established from a patient diagnosed with MDS progressed to 
overt leukemia, which is a desirable cell line for study on the effective mechanisms of 
As2S2 in the treatment of MDS or MDS/AML. This work shown in Chapter 4, to our 
knowledge, is the first discription that As2S2 can inhibit proliferation and viability, 
induce apoptosis, and concurrently promote erythroid differentiation in 
cytokine-dependent MDS-progressed human leukemia cell line F-36p with complex 
karyotype including -7. My investigation for the precise action mechanisms of As2S2 
in vitro in human malignant cells thus imply the rationale and future directions of 
As2S2 as a potential anticancer drug candidate. 
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